General References



da Costa KA, Kozyreva OG, Song J, Galanko JA, Fischer LM, Zeisel SH. Common genetic polymorphisms affect the human requirement for the nutrient choline. FASEB J 2006; 20:1336-44.

da Rocha MD, Viegas FP, Campos HC et al. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer’s disease. CNS Neurol Disord Drug Targets 2011; 10:251-70.

Daali Y, Ancrenaz V, Bosilkovska M, Dayer P, Desmeules J. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. Metabolism 2011; 60:1584-9.

Dabora SL, Roberts P, Nieto A et al. Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients. Am J Hum Genet 2002; 71:750-8.

Dabrowski MJ, Schrag ML, Wienkers LC, Atkins WM. Pyrene. pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J Am Chem Soc 2002; 124:11866-7.

Dadashzadeh S, Javadian B, Sadeghian S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos 2006; 27:329-34.

Dadkhah A, Allameh A, Khalafi H, Ashrafihelan J. Inhibitory effects of dietary caraway essential oils on 1,2-dimethylhydrazine-induced colon carcinogenesis is mediated by liver xenobiotic metabolizing enzymes. Nutr Cancer 2011; 63:46-54.

Dagle JM, Fisher TJ, Haynes SE et al. Cytochrome P450 (CYP2D6) genotype is associated with elevated systolic blood pressure in preterm infants after discharge from the neonatal intensive care unit. J Pediatr 2011; 159:104-9.

Dahabreh I, Terasawa T, Castaldi P, Trikalinos TA. CYP2D6 testing to predict response to tamoxifen in women with breast cancer. Pharmacogenomic. PLoS Curr 2010. doi:10. 1371/currents. RRN1176.

Dahan A, Amidon GL. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res 2009; 26:883-92.

Dahan A, Amidon GL. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 2009; 297:371-7.

Dahan A, Amidon GL. MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm 2010; 386:216-20.

Daher W, Pelinski L, Klieber S et al. In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos 2006; 34:667-82.

Dahiyat M, Cumming A, Harrington C et al. Association between Alzheimer’s disease and the NOS3 gene. Ann Neurol 1999; 46:664-7.

Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41:453-70.

Dahl ML, Iselius L, Alm C et al. Polymorphic 2-hydroxylation of desipramine. A population and family study. Eur J Clin Pharmacol 1993; 44:445-50.

Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274:516-20.

Dahl ML, Sjöqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 2000; 22:114-7.

Dahl N, Pigg M, Ristoff E et al. Missense mutations in the human glutathione synthetase gene result in severe metabolic acidosis, 5-oxoprolinuria, hemolytic anemia and neurological dysfunction. Hum Mol Genet 1997; 6:1147-52.

Dahlman I, Vaxillaire M, Nilsson M et al. Estrogen receptor alpha gene variants associate with type 2 diabetes and fasting plasma glucose. Pharmacogenet Genomics 2008; 18:967-75.

Dai CL, Liang YJ, Chen LM et al. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochem Pharmacol 2009; 78:355-64.

Dai CL, Liang YJ, Wang YS et al. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 2009; 279:74-83.

Dai CL, Xiong HY, Tang LF et al. Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. Cancer Chemother Pharmacol 2007; 60:741-50.

Dai D, Tang J, Rose R et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001; 299:825-31.

Dai D, Zeldin DC, Blaisdell JA et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597-607.

Dai GD, Cui LB, Song L et al. Metabolism of terephthalic acid and its effects on CYP4B1 induction. Biomed Environ Sci 2006; 19:8-14.

Dai J, Zhang F, Zheng J. Retrorsine, but not monocrotaline, is a mechanism-based inactivator of P450 3A4. Chem Biol Interact 2010; 183:49-56.

Dai Y, Grant S. Cyclin-dependent kinase inhibitors. Curr Opin Pharmacol 2003; 3:362-70.

Dai Y, Hebert MF, Isoherranen N et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34:836-47.

Dai Y, Iwanaga K, Lin YS et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 2004; 68:1889-902.

Dai Y, Wang Q, Zhang X et al. Molecular docking and QSAR study on steroidal compounds as aromatase inhibitors. Eur J Med Chem 2010; 45:5612-20.

Dai Z, Papp AC, Wang D, Hampel H, Sadee W. Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics 2008; 1:24.

Daigo S, Takahashi Y, Fujieda M et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002; 12:299-306.

Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 2009; 10:1489-510.

Dajani R, Hood AM, Coughtrie MW. A single amino acid, glu146, governs the substrate specificity of a human dopamine sulfotransferase, SULT1A3. Mol Pharmacol 1998; 54:942-8.

Dal Forno G, Carson KA, Brookmeyer R, Troncoso J, Kawas CH, Brandt J. APOE genotype and survival in men and women with Alzheimer’s disease. Neurology 2002; 58:1045-50.

Dalén P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63:444-52.

Dalén P, Dahl ML, Roh HK et al. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. Br J Clin Pharmacol 2003; 55:630-4.

Daley D, Lemire M, Akhabir L et al. Analyses of associations with asthma in four asthma population samples from Canada and Australia. Hum Genet 2009; 125:445-59.

Daley D, Lewis S, Platzer P et al. Identification of susceptibility genes for cancer in a genome-wide scan: results from the colon neoplasia sibling study. Am J Hum Genet 2008; 82:723-36.

Daly AK. Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 2004; 4:1733-44.

Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 2006; 45:13-31.

Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics 2010; 11:607-11.

Daly AK, Aithal GP. Genetic regulation of warfarin metabolism and response. Semin Vasc Med 2003; 3:231-8.

Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132:272-81.

Daly AK, Day CP, Donaldson PT. Polymorphisms in immunoregulatory genes: towards individualized immunosuppressive therapy? Am J Pharmacogenomics 2002; 2:13-23.

Daly AK, Donaldson PT, Bhatnagar P et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41:816-9.

Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996; 6:319-28.

Daly AK, Leathart JB, London SJ, Idle JR. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. Hum Genet 1995; 95:337-41.

Daly AK, Salh BS, Bilton D et al. Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindreds. Pharmacogenetics 1992; 2:19-24.

Dalley JW, Fryer TD, Brichard L et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007; 315:1267-70.

Dallongeville J, Cottel D, Montaye M, Codron V, Amouyel P, Helbecque N. Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men. Int J Cardiol 2006; 106:152-6.

Dallongeville J, Helbecque N, Cottel D, Amouyel P, Meirhaeghe A. The Gly16-Arg16 and Gln27-Glu27 polymorphisms of beta-2-adrenergic receptor are associated with metabolic syndrome in men. J Clin Endocr Metab 2003; 88:4862-6.

Dally H, Bartsch H, Jäger B et al. Genotype relationships in the CYP3A locus in Caucasians. Cancer Lett 2004; 207:95-9.

Dally H, Edler L, Jäger B et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 2003; 13:607-18.

Dam V, Morgan BT, Mazanek P, Hogarty MD. Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer 2006; 6:177.

Damani SB, Topol EJ. Emerging genomic applications in coronary artery disease. JACC Cardiovasc Interv 2011; 4:473-82.

D’Ambrosio RL, D’Andrea G, Cappucci F et al. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica 2004; 89:1510-6.

Damiani D, Tiribelli M, Michelutti A et al. Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. Leuk Res 2010; 34:942-5.

Damkier P, Brøsen K. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clin Pharmacol Ther 2000; 68:199-209.

Damkier P, Hansen LL, Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 1999; 48:829-38.

Damkier P, Hansen LL, Brøsen K. Rifampicin treatment greatly increases the apparent oral clearance of quinidine. Pharmacol Toxicol 1999; 85:257-62.

Damle BD, Uderman H, Biswas P, Crownover P, Lin C, Glue P. Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. Br J Clin Pharmacol 2009; 68:682-9.

Damme B, Darmer D, Pankow D. Induction of hepatic cytochrome P4502E1 in rats by acetylsalicylic acid or sodium salicylate. Toxicology 1996; 106:99-103.

Damnjanovic T, Milicevic R, Novkovic T et al. Association between the methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia in Serbian children. J Pediatr Hematol Oncol 2010; 32:148-50.

Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol 2004; 18:113-23.

Dan H, Wu J, Peng M et al. Hypolipidemic effects of Alismatis rhizome on lipid profile in mice fed high-fat diet. Saudi Med J 2011; 32:701-7.

Dandara C, Masimirembwa CM, Magimba A et al. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001; 57:11-7.

D’Andrea G, Brisdelli F, Bozzi A. AZT: an old drug with new perspectives. Curr Clin Pharmacol 2008; 3:20-37.

Danenberg HD, Grad E, Swaminathan RV et al. Neointimal formation is reduced after arterial injury in human crp transgenic mice. Atherosclerosis 2008; 201:85-91.

Danesi R, Pasqualetti G, Giovannetti E et al. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev 2009; 61:408-17.

Danesi R, Pasqualetti G, Giovannetti E, del Tacca M. The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer. J Thorac Oncol 2007; 2:27-30.

Dang DT, Chen F, Kohli M, Rago C, Cummins JM, Dang LH. Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res 2005; 65:9485-94.

Daniel F, Loriot MA, Seksik P et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis 2007; 13:19-23.

Daniel W. Metabolism of psychotropic drugs: pharmacological and clinical relevance. Pol J Pharmacol 1995; 47:367-79.

Daniel WA, Haduch A, Wójcikowski J. Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms. Eur Neuropsychopharmacol 2005; 15:103-10.

Daniele A, Cammarata R, Pasanisi F et al. Molecular analysis of the adiponectin gene in severely obese patients from southern Italy. Ann Nutr Metab 2008; 53:155-61.

Danks RA, Dorevitch M, Cummins JT, Byrne E. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS): adolescent onset with severe cerebral edema. Aust N Z J Med 1988; 18:69-72.

Dannenberg LO, Edenberg HJ. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 2006; 7:181.

Danpure CJ. Molecular aetiology of primary hyperoxaluria type 1. Nephron Exp Nephrol 2004; 98:39-44.

Danpure CJ, Birdsey GM, Rumsby G, Lumb MJ, Purdue PE, Allsop J. Molecular characterization and clinical use of a polymorphic tandem repeat in an intron of the human alanine:glyoxylate aminotransferase gene. Hum Genet 1994; 94:55-64.

Dansky HM, Barlow CB, Lominska C et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol 2001; 21:1662-7.

Dao TT, Kailasam MT, Parmer RJ et al. Expression of altered alpha2-adrenergic phenotypic traits in normotensive humans at genetic risk of hereditary (essential) hypertension. J Hypertens 1998; 16:779-92.

Daood M, Tsai C, Ahdab-Barmada M, Watchko JF. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 2008; 39:211-8.

Dapkunas J, Sazonovas A, Japertas P. Probabilistic prediction of the human CYP3A4 and CYP2D6 metabolism sites. Chem Biodivers 2009; 6:2101-6.

Darabi H, Czene K, Wedrén S et al. Genetic variation in the androgen estrogen conversion pathway in relation to breast cancer prognosticators. Breast Cancer Res Treat 2011; 127:503-9.

Darabi M, Ani M, Panjehpour M, Rabbani M, Movahedian A, Zarean E. Effect of estrogen receptor β A1730G polymorphism on ABCA1 gene expression response to postmenopausal hormone replacement therapy. Genet Test Mol Biomarkers 2011; 15:11-5.

Darabi M, Rabbani M, Ani M, Zarean E, Panjehpour M, Movahedian A. Increased leukocyte ABCA1 gene expression in post-menopausal women on hormone replacement therapy. Gynecol Endocrinol 2011; 27:701-5.

Darazy M, Balbaa M, Mugharbil A, Saeed H, Sidani H, Abdel-Razzak Z. CYP1A1, CYP2E1, and GSTM1 gene polymorphisms and susceptibility to colorectal and gastric cancer Among Lebanese. Genet Test Mol Biomarkers 2011; 15:423-9.

Darbar D, Kannankeril PJ, Donahue BS et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 2008; 15:1927-35.

Darbari DS, Minniti CP, Rana S, van den Anker J. Pharmacogenetics of morphine: Potential implications in sickle cell disease. Am J Hematol 2008; 83:233-6.

Darby JK, Pasta DJ, Wilson MG, Herbert J. Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. Clin Drug Investig 2008; 28:553-64.

Darby RA, Callaghan R, McMahon RM. P-glycoprotein inhibition; the past, the present and the future. Curr Drug Metab 2011; 12:722-31.

Darendeliler F, Fournet JC, Baş F et al. ABCC8 (SUR1) and KCNJ11 (KIR6. 2) mutations in persistent hyperinsulinemic hypoglycemia of infancy and evaluation of different therapeutic measures. J Pediatr Endocrinol Metab 2002; 15:993-1000.

Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Derm 1997; 133:853-7.

Darnell JE Jr, Henriksen MA, Lerner L, Zhang X. STAT3-dependent enhanceosome assembly and disassembly: synergy with GR for full transcriptional increase of the alpha 2-macroglobulin gene. Genes Dev 2003; 17:2564-77.

Darnell M, Karlsson JE, Owen A et al. Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells. Drug Metab Dispos 2010; 38:491-7.

Darrah R, McKone E, O’Connor C et al. EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity. Physiol Genomics 2010; 41:71-7.

Darreh-Shori T, Soininen H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer’s disease: a review of recent clinical studies. Curr Alzheimer Res 2010; 7:67-73.

D’Arrigo C, Migliardi G, Santoro V et al. Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacol Res 2005; 52:497-501.

Darsigny M, Babeu JP, Dupuis AA et al. Loss of hepatocyte-nuclear-factor-4alpha affects colonic ion transport and causes chronic inflammation resembling inflammatory bowel disease in mice. PLoS One 2009. doi:10. 1371/journal. pone. 0007609.

Darwish M, Kirby M, Robertson P Jr, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet 2008; 47:61-74.

Darwish WS, Ikenaka Y, Eldaly EA et al. Cytochrome P450 1A-dependent activities in deer, cattle and horses. J Vet Med Sci 2010; 72:561-6.

Darwish WS, Kawai Y, Ikenaka Y, Yamamoto H, Muroya T, Ishizuka M. Identification and phylogenetic analysis of novel cytochrome P450 1A genes from ungulate species. J Vet Med Sci 2010; 72:1237-41.

Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005; 280:12944-55.

Das A, Zhao J, Schatz GC, Sligar SG, van Duyne RP. Screening of type I and II drug binding to human cytochrome P450-3A4 in nanodiscs by localized surface plasmon resonance spectroscopy. Anal Chem 2009; 81:3754-9.

Das BC, Madhukumar AV, Anguiano J et al. Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR). Bioorg Med Chem Lett 2008; 18:3974-7.

Das I, Craig C, Funahashi Y et al. Notch oncoproteins depend on gamma-secretase/presenilin activity for processing and function. J Biol Chem 2004; 279:30771-80.

Das J, Ghosh J, Manna P, Sil PC. Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res 2010; 44:340-55.

Das PC, Cao Y, Cherrington N, Hodgson E, Rose RL. Fipronil induces CYP isoforms and cytotoxicity in human hepatocytes. Chem Biol Interact 2006; 164:200-14.

Das PC, Cao Y, Roset RL, Cherrington N, Hodgson E. Enzyme induction and cytotoxicity in human hepatocytes by chlorpyrifos and N,N-diethyl-m-toluamide (DEET). Drug Metabol Drug Interact 2008; 23:237-60.

Das PC, Streit TM, Cao Y et al. Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact 2008; 23:211-36.

Das S, Levinson B, Vulpe C, Whitney S, Gitschier J, Packman S. Similar splicing mutations of the Menkes/mottled copper-transporting ATPase gene in occipital horn syndrome and the blotchy mouse. Am J Hum Genet 1995; 56:570-6.

Das S, Makino S, Melman YF et al. Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillation. Heart Rhythm 2009; 6:1146-53.

Dasbiswas A, Shinde S, Dasbiswas D. S-metoprolol: the 2008 clinical review. J Indian Med Assoc 2008; 106:259-62.

Datta SK, Kumar V, Ahmed RS, Tripathi AK, Kalra OP, Banerjee BD. Effect of GSTM1 and GSTT1 double deletions in the development of oxidative stress in diabetic nephropathy patients. Indian J Biochem Biophys 2010; 47:100-3.

Datta SR, McQuillin A, Puri V et al. Failure to confirm allelic and haplotypic association between markers at the chromosome 6p22. 3 dystrobrevin-binding protein 1 (DTNBP1) locus and schizophrenia. Behav Brain Funct 2007; 3:50.

Davaalkham J, Hayashida T, Tsuchiya K, Gatanaga H, Nyamkhuu D, Oka S. Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population. Drug Metab Dispos 2009; 37:1991-3.

Dávalos A, Fernández-Hernando C, Cerrato F et al. Red grape juice polyphenols alter cholesterol homeostasis and increase LDL-receptor activity in human cells in vitro. J Nutr 2006; 136:1766-73.

Davar R, Oskouian H, Ahmadi S, Firouzabadi RD. GnRH antagonist/letrozole versus microdose GnRH agonist flare protocol in poor responders undergoing in vitro fertilization. Taiwan J Obstet Gynecol 2010; 49:297-301.

Davare MA, Avdonin V, Hall DD et al. A beta-2 adrenergic receptor signaling complex assembled with the Ca2+ channel Ca(V)1. 2. Science 2001; 293:98-101.

David JP, Mehic D, Bakiri L et al. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J Clin Invest 2005; 115:664-72.

David SP, Johnstone EC, Murphy MF et al. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug Alcohol Depend 2008; 98:77-85.

Davidson MH. Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions. J Cardiovasc Pharmacol Ther 2001; 6:219-29.

Davidson MH. Therapies targeting exogenous cholesterol uptake: new insights and controversies. Curr Atheroscler Rep 2011; 13:95-100.

Davidson SI, Liu Y, Danoy PA et al. Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese. Ann Rheum Dis 2011; 70:289-92.

Davidzon G, Mancuso M, Ferraris S et al. POLG mutations and Alpers syndrome. Ann Neurol 2005; 57:921-3.

Davies A, Jordanides NE, Giannoudis A et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009; 23:1999-2006.

Davies BJ, Coller JK, James HM, Somogyi AA, Horowitz JD, Sallustio BC. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. Br J Clin Pharmacol 2006; 61:321-5.

Davies BJ, Coller JK, Somogyi AA, Milne RW, Sallustio BC. CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos 2007; 35:128-38.

Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. Br J Clin Pharmacol 2008; 65:347-54.

Davies GF, Juurlink BH, Harkness TA. Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Des Devel Ther 2009; 3:79-88.

Davies M, Heikkilä T, McConkey GA, Fishwick CW, Parsons MR, Johnson AP. Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J Med Chem 2009; 52:2683-93.

Davies MA, Setola V, Strachan RT et al. Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J 2006; 6:42-51.

Davies MF, Tsui JY, Flannery JA, Li X, DeLorey TM, Hoffman BB. Augmentation of the noradrenergic system in alpha-2 adrenergic receptor deficient mice: anatomical changes associated with enhanced fear memory. Brain Res 2003; 986:157-65.

Davies NM, Windmeijer F, Martin RM et al. Use of genotype frequencies in medicated groups to investigate prescribing practice: APOE and statins as a proof of principle. Clin Chem 2011; 57:502-10.

Davies P, Fontaine SN, Moualla D, Wang X, Wright JA, Brown DR. Amyloidogenic metal-binding proteins: new investigative pathways. Biochem Soc Trans 2008; 36:1299-303.

Davies SJ, Eayrs S, Pratt P, Lennard MS. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol 2004; 57:464-72.

Davies SJ, Lennard MS, Ghahramani P, Pratt P, Robertson A, Potokar J. PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions. J Psychopharmacol 2007; 21:153-60.

Davies SJ, Westin AA, Castberg I et al. Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand 2010; 122:444-53.

Davis BR, Arnett DK, Boerwinkle E et al. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the genetics of hypertension-associated treatment study. Pharmacogenomics J 2007; 7:112-22.

Davis HR Jr, Lowe RS, Neff DR. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis 2011; 215:266-78.

Davis JD, Podolanczuk A, Donahue JE et al. Thyroid hormone levels in the prefrontal cortex of post-mortem brains of Alzheimer’s disease patients. Curr Aging Sci 2008; 1:175-81.

Davis MP. Buprenorphine in cancer pain. Support Care Cancer 2005; 13:878-87.

Davis MP. Does trazodone have a role in palliating symptoms? Support Care Cancer 2007; 15:221-4.

Davis-Dao CA, Tuazon ED, Sokol RZ, Cortessis VK. Male infertility and variation in CAG repeat length in the androgen receptor gene: a meta-analysis. J Clin Endocrinol Metab 2007; 92:4319-26.

Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 2010; 30:134-46.

Davydov DR, Baas BJ, Sligar SG, Halpert JR. Allosteric mechanisms in cytochrome P450 3A4 studied by high-pressure spectroscopy: pivotal role of substrate-induced changes in the accessibility and degree of hydration of the heme pocket. Biochemistry 2007; 46:7852-64.

Davydov DR, Davydova NY, Tsalkova TN, Halpert JR. Effect of glutathione on homo- and heterotropic cooperativity in cytochrome P450 3A4. Arch Biochem Biophys 2008; 471:134-45.

Davydov DR, Fernando H, Baas BJ, Sligar SG, Halpert JR. Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry 2005; 44:13902-13.

Davydov DR, Halpert JR, Renaud JP, Hui Bon Hoa G. Conformational heterogeneity of cytochrome P450 3A4 revealed by high pressure spectroscopy. Biochem Biophys Res Commun 2003; 312:121-30.

Davydov DR, Sineva EV, Sistla S et al. Electron transfer in the complex of membrane-bound human cytochrome P450 3A4 with the flavin domain of P450BM-3: The effect of oligomerization of the heme protein and intermittent modulation of the spin equilibrium. Biochim Biophys Acta 2009; 1797:378-90.

Daw EW, Payami H, Nemens EJ et al. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet 2000; 66:196-204.

Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 2001; 114:1179-87.

Dawson PA, Haywood J, Craddock AL et al. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem 2003; 278:33920-7.

Dayangac-Erden D, Karaduman A, Erdem-Yurter H. Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch Dermatol Res 2007; 299:487-91.

Dayer P, Desmeules J, Collart L. Pharmacology of tramadol. Drugs 1997; 53 Suppl 2:18-24.

Dayer P, Desmeules J, Striberni R. In vitro forecasting of drugs that may interfere with codeine bioactivation. Eur J Drug Metab Pharmacokinet 1992; 17:115-20.

de Almagro MC, Selga E, Thibaut R, Porte C, Noé V, Ciudad CJ. UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate. Biochem Pharmacol 2011; 81:60-70.

de Beer MC, Ji A, Jahangiri A et al. ATP binding cassette G1-dependent cholesterol efflux during inflammation. J Lipid Res 2011; 52:345-53.

de Berardinis V, Moulis C, Maurice M et al. Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol Pharmacol 2000; 58:542-51.

de Bie P, Muller P, Wijmenga C, Klomp LW. Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes. J Med Genet 2007; 44:673-88.

de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010; 9:628-42.

de Boer OJ, van der Meer JJ, Teeling P et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 2010; 220:499-508.

de Boussac H, Ratajewski M, Sachrajda I et al. The ERK1/2-hepatocyte nuclear factor 4alpha axis regulates human ABCC6 gene expression in hepatocytes. J Biol Chem 2010; 285:22800-8.

de Braekeleer E, Douet-Guilbert N, Morel F et al. Philadelphia chromosome-positive acute lymphoblastic leukemia: a cytogenetic study of 33 patients diagnosed between 1981 and 2008. Anticancer Res 2010; 30:569-73.

de Bruijn P, Kehrer DF, Verweij J, Sparreboom A. Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism. J Chromatogr B Biomed Sci Appl 2001; 753:395-400.

de Bruin ML, van Puijenbroek EP, Bracke M, Hoes AW, Leufkens HG. Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data. Pharmacoepidemiol Drug Saf 2006; 15:99-105.

de Bruyne S, Wyffels L, Boos TL et al. In vivo evaluation of [123I]-4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine, an iodinated SPECT tracer for imaging the P-gp transporter. Nucl Med Biol 2010; 37:469-77.

de Buyzere M. Selective genetic advantages for users of thiazide diuretics. Is there a case for the 460Trp variant of alpha-adducin? J Hypertens 2009; 27:24-7.

de Castro WV, Mertens-Talcott S, Rubner A, Butterweck V, Derendorf H. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem 2006; 54:249-55.

de Castro-Orós I, Pampín S, Cofán M et al. Promoter variant -204A > C of the cholesterol 7α-hydroxylase gene: association with response to plant sterols in humans and increased transcriptional activity in transfected HepG2 cells. Clin Nutr 2011; 30:239-46.

de Caterina R, Zampolli A. From asthma to atherosclerosis-5-lipoxygenase, leukotrienes, and inflammation. New Eng J Med 2004; 350:4-7.

de Cid R, Fonseca F, Gratacòs M et al. BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes Brain Behav 2008; 7:515-22.

de Clerck F, Somers Y, Mannaert E, Greenspan A, Eerdekens M. In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. Clin Ther 2004; 26:1261-73.

de Craemer D, van den Branden C, Pauwels M, Vamecq J. Peroxisome-proliferating effects of fenoprofen in mice. Lipids 1998; 33:539-43.

de Denus S, Zakrzewski M, Barhdadi A et al. Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. J Heart Lung Transplant 2011; 30:326-31.

de Denus S, Zakrzewski-Jakubiak M, Dubé MP et al. Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. Ann Pharmacother 2008; 42:925-32.

de Dios A, Shih C, López de Uralde B et al. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. J Med Chem 2005; 48:2270-3.

de Felice FG, Ferreira ST. Novel neuroprotective, neuritogenic and anti-amyloidogenic properties of 2,4-dinitrophenol: the gentle face of Janus. IUBMB Life 2006; 58:185-91.

de Felice FG, Houzel JC, Garcia-Abreu J et al. Inhibition of Alzheimer’s disease beta-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer’s therapy. FASEB J 2001; 15:1297-9.

de Franchis R, Buoninconti A, Mandato C et al. The C677T mutation of the 5,10-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy. J Med Genet 1998; 35:1009-13.

de Gasperi R, Gama Sosa MA, Wen PH, Li J, Perez GM, Curran T, Elder GA. Cortical development in the presenilin-1 null mutant mouse fails after splitting of the preplate and is not due to a failure of reelin-dependent signaling. Dev Dyn 2008; 237:2405-14.

de George BR Jr, Koch WJ. Beta blocker specificity: a building block toward personalized medicine. J Clin Invest 2007; 117:86-9.

de Gregorio L, Manenti G, Incarbone M et al. Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma. Int J Cancer 1998; 79:269-72.

de Groene EM, Hassing IG, Blom MJ, Seinen W, Fink-Gremmels J, Horbach GJ. Development of human cytochrome P450-expressing cell lines: application in mutagenicity testing of ochratoxin A. Cancer Res 1996; 56:299-304.

de Groene EM, Nijmeijer SM, Horbach GJ, Witkamp RF. Tiamulin inhibits human CYP3A4 activity in an NIH/3T3 cell line stably expressing CYP3A4 cDNA. Biochem Pharmacol 1995; 50:771-3.

de Groene EM, Seinen W, Horbach GJ. A NIH/3T3 cell line stably expressing human cytochrome P450-3A4 used in combination with a lacZ’ shuttle vector to study mutagenicity. Eur J Pharmacol 1995; 293:47-53.

de Groote P, Ennezat PV, Mouquet F. Bisoprolol in the treatment of chronic heart failure. Vasc Health Risk Manag 2007; 3:431-9.

de Groote P, Helbecque N, Lamblin N et al. Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure. Eur J Heart Fail 2004; 6:17-21.

de Groote P, Helbecque N, Lamblin N et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 2005; 15:137-42.

de Haas EC, Zwart N, Meijer C et al. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol 2008; 26:1817-23.

de Iudicibus S, de Pellegrin A, Stocco G, Bartoli F, Bussani R, Decorti G. ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer. Anticancer Res 2008; 28:3921-8.

de Jager PL, Jia X, Wang J et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41:776-82.

de Jager R, Cheverton P, Tamanoi K et al. DX-8951f: summary of phase I clinical trials. Ann N Y Acad Sci 2000; 922:260-73.

de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH. Role of pharmacogenetics in irinotecan therapy. Cancer Lett 2006; 234:90-106.

de Jong FA, Marsh S, Mathijssen RH et al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004; 10:5889-94.

de Jong FA, Scott-Horton TJ, Kroetz DL et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007; 81:42-9.

de Jonghe C, Esselens C, Kumar-Singh S et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect A-beta secretion and APP C-terminal fragment stability. Hum Mol Genet 2001; 10:1665-71.

de Jonghe C, Zehr C, Yager D et al. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis 1998; 5:281-6.

de Kauwe AL, Chen Z, Anderson RP et al. Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells. J Immunol 2009; 182:7440-50.

de Klein A, van Kessel AG, Grosveld G et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300:765-7.

de Klerk OL, Willemsen AT, Bosker FJ et al. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry Res 2010; 183:151-6.

de Krom M, Staal WG, Ophoff RA et al. A common variant in DRD3 receptor is associated with autism spectrum disorder. Biol Psychiatry 2009; 65:625-30.

de la Monte SM, Tong M. Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer’s disease. J Alzheimers Dis 2009; 17:817-25.

de la Torre R, Farré M, Roset PN et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 2004; 26:137-44.

de Leener A, Montanelli L, van Durme J et al. Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J Clin Endocrinol Metab 2006; 91:555-62.

de León DD, Stanley CA. Permanent neonatal diabetes mellitus. In: Pagon RA, Bird TC, Dolan CR, Stephens K (Eds). GeneReviews. University of Washington, Seattle, 1993-2008. Available from: http://www. ncbi. nlm. nih. gov/books/NBK1447/

de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009; 34:159-72.

de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005; 46:262-73.

de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006; 47:75-85.

de Leon J, Correa JC, Ruaño G, Windemuth A, Arranz MJ, Díaz FJ. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 2008; 98:40-6.

de Leon J, Diaz FJ, Wedlund P, Josiassen RC, Cooper TB, Simpson GM. Haloperidol half-life after chronic dosing. J Clin Psychopharmacol 2004; 24:656-60.

de Leon J, Nikoloff DM. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectr 2008; 13:133-5.

de Leon J, Susce MT, Johnson M et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr 2009; 14:19-34.

de Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther 2006; 10:135-51.

de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66:15-27.

de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005; 25:448-56.

de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010; 51:80-8.

de Lima EL, da Silva VC, da Silva HD et al. MTR polymorphic variant A2756G and retinoblastoma risk in Brazilian children. Pediatr Blood Cancer 2010; 54:904-8.

de Luca V, Muglia P, Vincent JB, Lanktree M, Jain U, Kennedy JL. Adrenergic alpha 2C receptor genomic organization: association study in adult ADHD. Am J Med Genet B Neuropsychiatr Genet 2004; 127:65-7.

de Luca V, Müller DJ, Hwang R et al. HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Hum Psychopharmacol 2007; 22:463-7.

de Luis DA, González Sagrado M, Aller R, Izaola O, Conde R. Influence of Trp64Arg polymorphism of beta 3-adrenoreceptor gene on insulin resistance, adipocytokines and weight loss secondary to two hypocaloric diets. Ann Nutr Metab 2009; 54:104-10.

de Luis DA, Sagrado MG, Aller R, Izaola O, Conde R. Influence of ALA54THR polymorphism of fatty acid-binding protein 2 on obesity and cardiovascular risk factors. Horm Metab Res 2007; 39:830-4.

de Luis DA, Sagrado MG, Aller R, Izaola O, Conde R, Romero E. Ala54Thr Polymorphism of Fatty Acid Binding Protein 2, Role on Insulin Resistance and Cardiovascular Risk Factors in Presurgical Morbid Obesity Patients. Obes Surg 2010; 19:1691-6.

de Maat MP, Jukema JW, Ye S et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999; 83:852-6.

de Maat MP, Kastelein JJ, Jukema JW et al. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. Arterioscler Thromb Vasc Biol 1998; 18:265-71.

de Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 2009; 45:1333-51.

de Meirleir L, Seneca S, Lissens W, Schoentjes E, Desprechins B. Bilateral striatal necrosis with a novel point mutation in the mitochondrial ATPase 6 gene. Pediat Neurol 1995; 13:242-6.

de Mey C, Althaus M, Ezan E, Retzow A. Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans. Clin Pharmacol Ther 2001; 70:142-8.

de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46:594-8.

de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269:15419-22.

de Palma G, Dick FD, Calzetti S et al. A case-control study of Parkinson’s disease and tobacco use: gene-tobacco interactions. Mov Disord 2010; 25:912-9.

de Paz B, Alperi-López M, Ballina-García FJ et al. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis-association with clinical response to glucocorticoids. J Rheumatol 2010; 37:503-11.

de Placido S, Carlomagno C, de Laurentiis M, Bianco AR. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. Breast Cancer Res Treat 1998; 52:55-64.

de Pontual L, Pelet A, Trochet D et al. Mutations of the RET gene in isolated and syndromic Hirschsprung’s disease in human disclose major and modifier alleles at a single locus. J Med Genet 2006; 43:419-23.

de Raedt T, Cools J, Debiec-Rychter M et al. Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology 2006; 131:1907-12.

de Rooij K, Dorsman J, Smoor M, den Dunnen J, van Ommen G. Subnuclear localization of the Huntington’s disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. Hum Molec Genet 1996; 5:1093-9.

de Silva R, Ironside JW, McCardle L et al. Neuropathological phenotype and ‘prion protein’ genotype correlation in sporadic Creutzfeldt-Jakob disease. Neurosci Lett 1994; 179:50-2.

de Strooper B, Saftig P, Craessaerts K et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391:387-90.

de Velde F, Alffenaar JW, Wessels AM, Greijdanus B, Uges DR. Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:1771-7.

de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 2011; 11:359-67.

de Vries E, Koene HR, Vossen JM et al. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 1996; 88:3022-7.

de Vries HS, te Morsche RH, van Oijen MG, Nagtegaal ID, Peters WH, de Jong DJ. The functional -765G→C polymorphism of the COX-2 gene may reduce the risk of developing crohn’s disease. PLoS One 2010. doi:10. 1371/journal. pone. 0015011.

de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 2010. doi:10. 1007/s10637-010-9569-1.

de Waard MC, van der Pluijm I, Zuiderveen Borgesius N et al. Age-related motor neuron degeneration in DNA repair-deficient Ercc1 mice. Acta Neuropathol 2010; 120:461-75.

de Waart DR, Häusler S, Vlaming ML et al. Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein. J Pharmacol Exp Ther 2010; 334:78-86.

de Waart DR, Vlaming ML, Kunne C, Schinkel AH, Oude Elferink RP. Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos 2009; 37:1698-702.

de Wet H, Fotinou C, Amad N, Dreger M, Ashcroft FM. The ATPase activities of sulfonylurea receptor 2A and sulfonylurea receptor 2B are influenced by the C-terminal 42 amino acids. FEBS J 2010; 277:2654-62.

de Wildt SN, Berns MJ, van den Anker JN. 13C-erythromycin breath test as a noninvasive measure of CYP3A activity in newborn infants: a pilot study. Ther Drug Monit 2007; 29:225-30.

de Wildt SN, Kearns GL, Hop WC et al. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther 2001; 70:525-31.

de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 2002; 53:390-2.

de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37:485-505.

de Wildt SN, Kearns GL, Murry DJ, Koren G, van den Anker JN. Ontogeny of midazolam glucuronidation in preterm infants. Eur J Clin Pharmacol 2010; 66:165-70.

Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003; 23:2083-9.

Dean B, Laws SM, Hone E et al. Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry 2003; 54:616-22.

Dean B, Soulby A, Evin GM, Scarr E. Levels of [(3)H]pirenzepine binding in Brodmann’s area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1. Schizophr Res 2008; 106:229-36.

Dean BJ, Chang S, Silva Elipe MV et al. Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans. Drug Metab Dispos 2007; 35:283-92.

Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-62.

DeArmond SJ, Ironside JW. Neuropathology of prion disease. In: Prusiner SB (Ed). Prion biology and diseases. Cold Spring Harbor Laboratory Press, New York, 1999:585-652.

Deary IJ, Whiteman MC, Pattie A et al. Cognitive change and the APOE epsilon-4 allele. Nature 2002; 418:932.

Deb GK, Dey SR, Bang JI et al. 9-cis retinoic acid improves developmental competence and embryo quality during in vitro maturation of bovine oocytes through the inhibition of oocyte tumor necrosis factor-{alpha} gene expression. J Anim Sci 2011; 89:2759-67.

Deb S, Bandiera SM. Regulation of cytochrome P450 1B1 expression by luteinizing hormone in mouse MA-10 and rat R2C Leydig cells: role of protein kinase A. Biol Reprod 2011; 85:89-96.

Debelenko LV, Brambilla E, Agarwal SK et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Molec Genet 1997; 6:2285-90.

Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet 2001; 40:441-72.

Decano JL, Viereck JC, McKee AC, Hamilton JA, Ruiz-Opazo N, Herrera VL. Early-life sodium exposure unmasks susceptibility to stroke in hyperlipidemic, hypertensive heterozygous Tg25 rats transgenic for human cholesteryl ester transfer protein. Circulation 2009; 119:1501-9.

Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998; 87:803-7.

Declerck E, de Loof H, de Meyer GR. Statins under fire: justified or not? J Pharm Belg 2009:119-30.

Declèves X, Jacob A, Yousif S, Shawahna R, Potin S, Scherrmann JM. Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr Drug Metab 2011; 12:732-41.

Decottignies A, Goffeau A. Complete inventory of the yeast ABC proteins. Nat Genet 1997; 15:137-45.

Deeb SS, Fajas L, Nemoto M et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20:284-7.

Deeken JF, Cormier T, Price DK et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J 2010; 10:191-9.

Deeken JF, Robey RW, Shukla S et al. Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol 2009; 76:946-56.

Deelen J, Beekman M, Uh HW et al. Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. Aging Cell 2011; 10:686-98.

Deeni YY, Paine MJ, Ayrton AD, Clarke SE, Chenery R, Wolf CR. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein. Arch Biochem Biophys 2001; 396:16-24.

Degerli N, Yilmaz E, Bardakci F. The delta32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem 2005; 38:248-52.

Degnan AP, Chaturvedula PV, Conway CM et al. Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J Med Chem 2008; 51:4858-61.

Degousee N, Fazel S, Angoulvant D et al. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 2008; 117:1701-10.

Dehal SS, Kupfer D. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 1999; 27:681-8.

Dehning S, Müller N, Matz J et al. A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome. Psychiatr Genet 2010; 20:35-8.

Deierborg T, Wieloch T, Diano S, Warden CH, Horvath TL, Mattiasson G. Overexpression of UCP2 protects thalamic neurons following global ischemia in the mouse. J Cereb Blood Flow Metab 2008; 28:1186-95.

Dejeux E, Rønneberg JA, Solvang H et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer 2010; 9:68.

Deka M, Bose M, Baruah B et al. Role of CYP2E1 gene polymorphisms association with hepatitis risk in Northeast India. World J Gastroenterol 2010; 16:4800-8.

DeKeyser JG, Stagliano MC, Auerbach SS, Prabhu KS, Jones AD, Omiecinski CJ. Di(2-ethylhexyl) phthalate is a highly potent agonist for the human constitutive androstane receptor splice variant CAR2. Mol Pharmacol 2009; 75:1005-13.

del Bo R, Comi GP, Giorda R et al. The 129 codon polymorphism of the prion protein gene influences earlier cognitive performance in Down syndrome subjects. J Neurol 2003; 250:688-92.

del Bo R, Scarlato M, Ghezzi S et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol 2005; 57:373-80.

del Mastro L, Levaggi A, Giraudi S, Pronzato P. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives. Cancer Treat Rev 2011; 37:208-11.

Delacourte A, Sergeant N, Champain D et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease. Neurology 2002; 59:398-407.

Delaloy C, Hadchouel J, Imbert-Teboul M, Clemessy M, Houot AM, Jeunemaitre X. Cardiovascular expression of the mouse WNK1 gene during development and adulthood revealed by a BAC reporter assay. Am J Pathol 2006; 169:105-18.

Delanghe JR, Langlois MR, de Buyzere ML, Torck MA. Vitamin C deficiency and scurvy are not only a dietary problem but are codetermined by the haptoglobin polymorphism. Clin Chem 2007; 53:1397-400.

Delhanty JD, Cooke HM. Increased chromosome breakage by N-methyl-N1-nitro-N-nitrosoguanidine in patients with adenomatous polyposis coli. Cancer Genet Cytogenet 1989; 42:263-71.

D’Elia P, de Matteis F, Dragoni S, Shah A, Sgaragli G, Valoti M. DP7, a novel dihydropyridine multidrug resistance reverter, shows only weak inhibitory activity on human CYP3A enzyme(s). Eur J Pharmacol 2009; 614:7-13.

Delić D, Dkhil M, Al-Quraishy S, Wunderlich F. Hepatic miRNA expression reprogrammed by Plasmodium chabaudi malaria. Parasitol Res 2011; 108:1111-21.

Delić D, Ellinger-Ziegelbauer H, Vohr HW, Dkhil M, Al-Quraishy S, Wunderlich F. Testosterone response of hepatic gene expression in female mice having acquired testosterone-unresponsive immunity to Plasmodium chabaudi malaria. Steroids 2011; 76:1204-12.

Delisle MB, Murrell JR, Richardson R et al. A mutation at codon 279 (N279K) in exon 10 of the tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropath 1999; 98:62-77.

DeLoia JA, Zamboni WC, Jones JM, Strychor S, Kelley JL, Gallion HH. Expression and activity of taxane-metabolizing enzymes in ovarian tumors. Gynecol Oncol 2008; 108:355-60.

Delou JM, Capella MA, Gattass CR. Betulinic acid does not modulate the activity of P-gp/ABCB1 or MRP1/ABCC1 in a non-tumoral renal cell line: Possible utility in multidrug resistance cancer chemotherapy. Mol Med Report 2009; 2:271-5.

Delozier TC, Kissling GE, Coulter SJ et al. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 2007; 35:682-8.

DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 2005; 315:1085-90.

Delvaeye M, Noris M, de Vriese A et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:345-57.

Dellapasqua S, Colleoni M. Letrozole. Expert Opin Drug Metab Toxicol 2010; 6:251-9.

Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, Lazarus P. Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10. Carcinogenesis 2007; 28:2412-8.

Dellinger RW, Fang JL, Chen G, Weinberg R, Lazarus P. Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos 2006; 34:943-9.

Demaria M, Giorgi C, Lebiedzinska M et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging 2010; 2:823-42.

DeMattos RB, Cirrito JR, Parsadanian M et al. ApoE and clusterin cooperatively suppress A-beta levels and deposition: evidence that ApoE regulates extracellular A-beta metabolism in vivo. Neuron 2004; 41:193-202.

DeMichele A, Aplenc R, Botbyl J et al. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 2005; 23:5552-9. Erratum in: J Clin Oncol 2007; 25:5675-7. Retraction in: J Clin Oncol 2006; 24:3315.

Demichele-Sweet MA, Lopez OL, Sweet RA. Psychosis in Alzheimer’s disease in the national Alzheimer’s disease coordinating center uniform data set: clinical correlates and association with apolipoprotein E. Int J Alzheimers Dis 2011. doi:10. 4061/2011/926597.

Demokan S, Suoglu Y, Gözeler M, Demir D, Dalay N. N-acetyltransferase 1 and 2 gene sequence variants and risk of head and neck cancer. Mol Biol Rep 2010; 37:3217-26.

D’empaire I, Guico-Pabia CJ, Preskorn SH. Antidepressant treatment and altered CYP2D6 activity: Are pharmacokinetic variations clinically relevant? J Psychiatr Pract 2011; 17:330-9.

Demura M, Demura Y, Ameshima S et al. Changes in aromatase (CYP19) gene promoter usage in non-small cell lung cancer. Lung Cancer 2011; 73:289-93.

Demura M, Wang F, Yoneda T et al. Multiple noncoding exons 1 of nuclear receptors NR4A family (nerve growth factor-induced clone B, Nur-related factor 1 and neuron-derived orphan receptor 1) and NR5A1 (steroidogenic factor 1) in human cardiovascular and adrenal tissues. J Hypertens 2011; 29:1185-95.

den Broeder MJ, van der Linde H, Brouwer JR, Oostra BA, Willemsen R, Ketting RF. Generation and characterization of FMR1 knockout zebrafish. PLoS One 2009. doi:10. 1371/journal. pone. 0007910.

Den Dunen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000; 15:7-12.

den Hartog JE, Lyons JM, Ouburg S et al. TLR4 in Chlamydia trachomatis infections: knockout mice, STD patients and women with tubal factor subfertility. Drugs Today 2009; 45 Suppl B:75-82.

den Uyl D, van der Horst-Bruinsma IE, van Agtmael M. Progression of HIV to AIDS: a protective role for HLA-B27? AIDS Rev 2004; 6:89-96.

Deng CN, Shen LH, Tang CS. Effect of spironolactone on L-arginine/iNOS/NO pathway of aortic adventitia in spontaneously hypertensive rats. Zhonghua Yi Xue Za Zhi 2010; 90:424-6.

Deng CX, Wang RH. Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum Molec Genet 2003; 12:113-23.

Deng G, Zhou G, Zhai Y et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology 2004; 40:318-26.

Deng GH, Zhou X, Pang ZY, Liu SM, Xie Y. Study on mitochondrial function of ND1 gene with 3316 G→A mutation in human diabetes. Zhonghua Yi Xue Za Zhi 2009; 89:2822-6.

Deng HB, Jiang CQ, Tomlinson B et al. A polymorphism in transforming growth factor-β1 is associated with carotid plaques and increased carotid intima-media thickness in older Chinese men: The Guangzhou Biobank Cohort Study-Cardiovascular Disease Subcohort. Atherosclerosis 2011; 214:391-6.

Deng LJ, Wang F, Li HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005; 61:831-6.

Deng Q, Li ZP, Huang CM et al. Effect and mechanism of DNMT inhibitor on the reversal of multidrug resistance in human colon cancer cell line sw620/L-OHP. Sichuan Da Xue Xue Bao Yi Xue Ban 2010; 41:975-9.

Deng R, Yang D, Radke A, Yang J, Yan B. The hypolipidemic agent guggulsterone regulates the expression of human bile salt export pump: dominance of transactivation over farsenoid X receptor-mediated antagonism. J Pharmacol Exp Ther 2007; 320:1153-62.

Deng S, Zhu G, Liu F et al. CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:664-8.

Deng Y, Edin ML, Theken KN et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 2011; 25:703-13.

Deng Y, Newman B, Dunne MP, Silburn PA, Mellick GD. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson’s disease. Ann Neurol 2004; 55:897.

Deng Y, Newman B, Dunne MP, Silburn PA, Mellick GD. Case-only study of interactions between genetic polymorphisms of GSTM1, P1, T1 and Z1 and smoking in Parkinson’s disease. Neurosci Lett 2004; 366:326-31.

Denisov IG, Baas BJ, Grinkova YV, Sligar SG. Cooperativity in cytochrome P450 3A4: linkages in substrate binding, spin state, uncoupling, and product formation. J Biol Chem 2007; 282:7066-76.

Denisov IG, Grinkova YV, Baas BJ, Sligar SG. The ferrous-dioxygen intermediate in human cytochrome P450 3A4. Substrate dependence of formation and decay kinetics. J Biol Chem 2006; 281:23313-8.

Denisov IG, Grinkova YV, McLean MA, Sligar SG. The one-electron autoxidation of human cytochrome P450 3A4. J Biol Chem 2007; 282:26865-73.

Deniz M, Bayazit YA, Celenk F et al. Significance of serotonin transporter gene polymorphism in tinnitus. Otol Neurotol 2010; 31:19-24.

Denk GU, Aslanidis C, Schmitz G, Parhofer KG, Pusl T. Association of HDL deficiency with a novel mutation in the ABCA1 gene. Exp Clin Endocrinol Diabetes 2011; 119:53-5.

Denlinger CS, Blanchard R, Xu L et al. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009; 65:97-105.

Dennison JB, Jones DR, Renbarger JL, Hall SD. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 2007; 321:553-63.

Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006; 34:1317-27.

Dennison JB, Mohutsky MA, Barbuch RJ, Wrighton SA, Hall SD. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther 2008; 327:248-57.

Dentice M, Marsili A, Ambrosio R et al. The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration. J Clin Invest 2010; 120:4021-30.

Denucci SM, Tong M, Longato L et al. Rat strain differences in susceptibility to alcohol-induced chronic liver injury and hepatic insulin resistance. Gastroenterol Res Pract 2010. doi:10. 1155/2010/312790.

Denys D, van Nieuwerburgh F, Deforce D, Westenberg HG. Association between serotonergic candidate genes and specific phenotypes of obsessive compulsive disorder. J Affect Disord 2006; 91:39-44.

Denzel MS, Hebbard LW, Shostak G, Shapiro L, Cardiff RD, Ranscht B. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res 2009; 15:3256-64.

Deo AK, Bandiera SM. Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid. Drug Metab Dispos 2008; 36:1983-91.

Deo AK, Bandiera SM. 3-ketocholanoic acid is the major in vitro human hepatic microsomal metabolite of lithocholic acid. Drug Metab Dispos 2009; 37:1938-47.

Deonna T, Arczynska W, Torrado A. Congenital failure of automatic ventilation (Ondine’s curse). J Pediat 1974; 84:710-4.

Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol 2011; 18:1159-64.

Dere E, Zlomuzica A, Viggiano D et al. Episodic-like and procedural memory impairments in histamine H1 Receptor knockout mice coincide with changes in acetylcholine esterase activity in the hippocampus and dopamine turnover in the cerebellum. Neuroscience 2008; 157:532-41.

Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008; 30:1956-75.

Dergunov AD. Local/bulk determinants of conformational stability of exchangeable apolipoproteins. Biochim Biophys Acta 2011; 1814:1169-77.

Dergunov AD. Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: Mechanistic and clinical studies. Biomed Pharmacother 2011. doi:10. 1016/j. biopha. 2011. 04. 003.

Derks M, Fowler S, Kuhlmann O. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin Ther 2009; 31:586-99.

Derks M, Fowler S, Kuhlmann O. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 2009; 25:891-902.

Dermaut B, Croes EA, Rademakers R et al. PRNP Val129 homozygosity increases risk for early-onset Alzheimer’s disease. Ann Neurol 2003; 53:409-12.

Dermaut B, Kumar-Singh S, Engelborghs S et al. A novel presenilin 1 mutation associated with Pick’s disease but not beta-amyloid plaques. Ann Neurol 2004; 55:617-26.

Deroussent A, Ré M, Hoellinger H, Cresteil T. Metabolism of sanguinarine in human and in rat: characterization of oxidative metabolites produced by human CYP1A1 and CYP1A2 and rat liver microsomes using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2010; 52:391-7.

Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50:2766-74.

Dervieux T, Furst D, Lein DO et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005; 64:1180-5.

Dervieux T, Kremer J, Lein DO et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004; 14:733-9.

Desai AA, Innocenti F, Janisch L et al. A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol 2004; 54:377-84.

Desai M, Tanus-Santos JE, Li L et al. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J 2003; 3:105-13.

Desai PB, Duan J, Sridhar R, Damle BD. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole. Methods Find Exp Clin Pharmacol 1997; 19:231-9.

Desai PB, Duan JZ, Zhu YW, Kouzi S. Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 1998; 23:417-24.

Desai PB, Nallani SC, Sane RS et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 2002; 30:608-12.

Desai R, Ruesch D, Forman SA. Gamma-amino butyric acid type A receptor mutations at beta2N265 alter etomidate efficacy while preserving basal and agonist-dependent activity. Anesthesiology 2009; 111:774-84.

Deslys JP, Jaegly A, d’Aignaux JH, Mouthon F, de Villemeur TB, Dormont D. Genotype at codon 129 and susceptibility to Creutzfeldt-Jakob disease. Lancet 1998; 351:1251.

Desmeules J, Gascon MP, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41:23-6.

Desrivières S, Lourdusamy A, Müller C et al. Glucocorticoid receptor (NR3C1) gene polymorphisms and onset of alcohol abuse in adolescents. Addict Biol 2011; 16:510-3.

Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999; 65:10-20.

Desta Z, Kerbusch T, Soukhova N, Richard E, Ko JW, Flockhart DA. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998; 285:428-37.

Desta Z, Soukhova N, Mahal SK, Flockhart DA. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos 2000; 28:789-800.

Desta Z, Soukhova N, Morocho AM, Flockhart DA. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. J Pharmacol Exp Ther 2001; 298:508-20.

Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310:1062-75.

Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 2002; 30:336-43.

Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913-58.

Desuzinges-Mandon E, Arnaud O, Martinez L, Huché F, di Pietro A, Falson P. ABCG2 transports and transfers heme to albumin through its large extracellular loop. J Biol Chem 2010; 285:33123-33.

Dettling M, Sachse C, Brockmöller J et al. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology 2000; 152:80-6.

Dettling M, Sachse C, Müller-Oerlinghausen B et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000; 33:218-20.

Deuchar GA, McLean D, Hadoke PW et al. 11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice. Endocrinology 2011; 152:236-46.

Deupree JD, Smith SD, Kratochvil CJ et al. Possible involvement of alpha-2A adrenergic receptors in attention deficit hyperactivity disorder: radioligand binding and polymorphism studies. Am J Med Genet B Neuropsychiatr Genet 2006; 141:877-84.

Deuschle M, Schredl M, Schilling C et al. Association between a serotonin transporter length polymorphism and primary insomnia. Sleep 2010; 33:343-7.

DeVane CL, Donovan JL, Liston HL et al. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol 2004; 24:4-10.

DeVane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry 1997; 58 Suppl 5:7-14.

DeVane CL, Markowitz JS, Carson SW et al. Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. J Clin Psychopharmacol 2000; 20:347-9.

DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40:509-22.

Devedjian JC, Pujol A, Cayla C et al. Transgenic mice overexpressing alpha2A-adrenoceptors in pancreatic beta-cells show altered regulation of glucose homeostasis. Diabetologia 2000; 43:899-906.

Devlin AH, McIlroy M, McKeen HD et al. Cytochrome P450 1B1 expression in rat esophageal tumorigenesis promoted by gastric and duodenal reflux. Mol Carcinog 2009; 48:110-7.

Devlin AH, Thompson P, Robson T, McKeown SR. Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translation. Mol Carcinog 2010; 49:190-9.

Devold HM, Molden E, Skurtveit S, Furu K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Br J Clin Pharmacol 2009; 67:234-41.

Devonshire HW, Kong I, Cooper M, Sloan TP, Idle JR, Smith RL. The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition. Brit J Clin Pharm 1983; 16:157-66.

DeVos L, Chanson A, Liu Z et al. Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations. Am J Clin Nutr 2008; 88:1149-58.

Devys D, Biancalana V, Rousseau F, Boué J, Mandel JL, Oberlé I. Analysis of full fragile X mutations in fetal tissues and monozygotic twins indicate that abnormal methylation and somatic heterogeneity are established early in development. Am J Med Genet 1992; 43:208-16.

Dewar AL, Cambareri AC, Zannettino AC et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105:3127-32.

Dewar JC, Wilkinson J, Wheatley A et al. The glutamine 27 beta-2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immun 1997; 100:261-5.

Dey A, Kumar SM. Cytochrome P450 2E1 and hyperglycemia-induced liver injury. Cell Biol Toxicol 2011; 27:285-310.

Dhaenens CM, Burnouf S, Simonin C et al. A genetic variation in the ADORA2A gene modifies age at onset in Huntington’s disease. Neurobiol Dis 2009; 35:474-6.

Dhaini HR, Thomas DG, Giordano TJ et al. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 2003; 21:2481-5.

Dhar M, Sepkovic DW, Hirani V, Magnusson RP, Lasker JM. Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11. J Lipid Res 2008; 49:612-24.

Dhikav V, Anand K. Potential predictors of hippocampal atrophy in Alzheimer’s disease. Drugs Aging 2011; 28:1-11.

Dhillon VS, Thomas P, Iarmarcovai G, Kirsch-Volders M, Bonassi S, Fenech M. Genetic polymorphisms of genes involved in DNA repair and metabolism influence micronucleus frequencies in human peripheral blood lymphocytes. Mutagenesis 2011; 26:33-42.

Dhiman N, Haralambieva IH, Kennedy RB et al. SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine. Immunogenetics 2010; 62:197-210.

Dhiman N, Ovsyannikova IG, Cunningham JM et al. Associations between measles vaccine immunity and single-nucleotide polymorphisms in cytokine and cytokine receptor genes. J Infect Dis 2007; 195:21-9.

Dhiman N, Ovsyannikova IG, Vierkant RA et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 2008; 26:1731-6.

Dhiman N, Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population. Tissue Antigens 2008; 72:211-20.

Dhir RN, Dworakowski W, Thangavel C, Shapiro BH. Sexually dimorphic regulation of hepatic isoforms of human cytochrome p450 by growth hormone. J Pharmacol Exp Ther 2006; 316:87-94.

Dhitavat S, Ortiz D, Rogers E, Rivera E, Shea TB. Folate, vitamin E, and acetyl-L-carnitine provide synergistic protection against oxidative stress resulting from exposure of human neuroblastoma cells to amyloid-beta. Brain Res 2005; 1061:114-7.

Di Bartolomeo S, Luly P, Spinedi A. P-glycoprotein is not a key target for the chemosensitizing effect of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol in HepG2 cells exposed to doxorubicin. Drug Metab Lett 2010; 4:39-44.

Di Consiglio E, Meneguz A, Testai E. Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s. Toxicol Appl Pharmacol 2005; 205:237-46.

Di Fede G, Catania M, Morbin M et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009; 323:1473-7.

Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166-9.

Di Fiore F, Michel P. Prognostic role of KRAS mutation in colorectal cancer. Bull Cancer 2009; 96 Suppl:23-30.

Di Iulio J, Fayet A, Arab-Alameddine M et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19:300-9.

Di L, Kerns EH, Li SQ, Carter GT. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. Int J Pharm 2007; 335:1-11.

Di Marco A, Marcucci I, Verdirame M et al. Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. Drug Metab Dispos 2005; 33:349-58.

Di Nardo G, Fantuzzi A, Sideri A et al. Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem 2007; 12:313-23.

Di Natale M, Perri M, Kawarai T et al. Absence of association between Alzheimer disease and the regulatory region polymorphism on the PS2 gene in an Italian population. Neurosci Lett 2003; 343:210-2.

Di Paolo A, Bocci G, Danesi R, del Tacca M. Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr Clin Pharmacol 2006; 1:311-23.

Di Pasquale P, Cannizzaro S, Paterna S. Does angiotensin-converting enzyme gene polymorphism affect blood pressure? Findings after 6 years of follow-up in healthy subjects. Eur J Heart Fail 2004; 6:11-6.

Di YM, Chow VD, Yang LP, Zhou SF. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab 2009; 10:754-80.

Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John’s wort and implication in drug development. Curr Pharm Des 2008; 14:1723-42.

Diamanti AP, Rosado M, Germano V et al. Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A: modulation of P-glycoprotein function. Clin Immunol 2011; 138:9-13.

Diao L, Li N, Brayman TG, Hotz KJ, Lai Y. Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-{alpha}, IL-6, and IL-1{beta}. J Biol Chem 2010; 285:31185-92.

Dias V, Ribeiro V. The expression of the solute carriers NTCP and OCT-1 is regulated by cholesterol in HepG2 cells. Fundam Clin Pharmacol 2007; 21:445-50.

Diaz DS, Kozar MP, Smith KS et al. Role of specific cytochrome P450 isoforms in the conversion of phenoxypropoxybiguanide analogs in human liver microsomes to potent antimalarial dihydrotriazines. Drug Metab Dispos 2008; 36:380-5.

Díaz FJ, Meary A, Arranz MJ, Ruaño G, Windemuth A, de León J. Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophr Res 2009; 115:136-40.

Diaz GJ, Murcia HW, Cepeda SM. Bioactivation of aflatoxin B1 by turkey liver microsomes: responsible cytochrome P450 enzymes. Br Poult Sci 2010; 51:828-37.

Diaz GJ, Murcia HW, Cepeda SM. Cytochrome P450 enzymes involved in the metabolism of aflatoxin B1 in chickens and quail. Poult Sci 2010; 89:2461-9.

Diaz GJ, Squires EJ. Metabolism of 3-methylindole by porcine liver microsomes: responsible cytochrome P450 enzymes. Toxicol Sci 2000; 55:284-92.

Diaz J, Vizuete ML, Traiffort E, Arrang JM, Ruat M, Schwartz JC. Localization of the histamine H2 receptor and gene transcripts in rat stomach: back to parietal cells. Biochem Biophys Res Commun 1994; 198:1195-202.

Diaz Z, Mann KK, Marcoux S et al. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia 2008; 22:1853-63.

Díaz-Cruz ES, Sugimoto Y, Gallicano GI, Brueggemeier RW, Furth PA. Comparison of increased Aromatase versus ER{alpha} in the generation of mammary hyperplasia and cancer. Cancer Res 2011; 71:5477-87.

Dick FD, de Palma G, Ahmadi A et al. Gene-environment interactions in parkinsonism and Parkinson’s disease: the Geoparkinson study. Occup Environ Med 2007; 64:673-80.

Dickens MJ, Cornil CA, Balthazart J. Acute stress differentially affects aromatase activity in specific brain nuclei of adult male and female quail. Endocrinology 2011; 152:4242-51.

Dickerson TJ, Janda KD. Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer’s disease. Proc Natl Acad Sci USA 2003; 100:8182-7.

Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 2011; 39:1415-22.

Dickmann LJ, Rettie AE, Kneller MB et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001; 60:382-7.

Dickmann LJ, Tay S, Senn TD et al. Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy. Biochem Pharmacol 2008; 75:1677-87.

Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009; 16:36-43.

Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, Bertilsson L. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol 2009; 67:38-43.

Diczfalusy U, Miura J, Roh HK et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 2008; 18:201-8.

Diczfalusy U, Olofsson KE, Carlsson AM et al. Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. J Lipid Res 2009; 50:2258-64.

Dichgans M, Freilinger T, Eckstein G et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005; 366:371-7.

Dideberg V, Louis E, Farnir F et al. Lymphotoxin alpha gene in Crohn’s disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet Genomics 2006; 16:369-73.

Diedrich A, Bock HC, König F et al. Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. Histol Histopathol 2006; 21:1199-207.

Diefenbach K, Jaeger K, Wollny A, Penzel T, Fietze I, Roots I. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype. Sleep Med 2008; 9:579-82.

Dierks A, Lichtenauer UD, Sackmann S et al. Identification of adrenal genes regulated in a potassium-dependent manner. J Mol Endocrinol 2010; 45:193-206.

Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 2001; 29:23-9.

Dieterle W, Mann J. Pharmacokinetic interaction between ketoconazole and SPP301 in healthy volunteers. Int J Clin Pharmacol Ther 2006; 44:326-30.

Dietrich C, Kaina B. The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 2010; 31:1319-28.

Dietrich CG, Ottenhoff R, de Waart DR, Oude Elferink RP. Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 2001; 167:73-81.

Dieudé P, Osorio J, Petit-Teixeira E et al. A TNFR1 genotype with a protective role in familial rheumatoid arthritis. Arthritis Rheum 2004; 50:413-9.

Dieudonné AS, Lambrechts D, Claes B et al. Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users. Breast Cancer Res Treat 2009; 118:531-8.

DiFligia M, Sapp E, Chase K et al. Aggregation of huntingtin in neuronal intracellular inclusions and dystrophic neurites in brain. Science 1997; 277:1990-3.

DiGeorge AM, Auerbach VH. Leucine-induced hypoglycemia: a review and speculations. Am J Med Sci 1960; 240:792-801.

Digoxin: serious drug interactions. Prescrire Int 2010; 19:68-70.

Dijkstra A, Howard TD, Vonk JM et al. Estrogen receptor 1 polymorphisms are associated with airway hyperresponsiveness and lung function decline, particularly in female subjects with asthma. J Allergy Clin Immunol 2006; 117:604-11.

Dijkstra A, Koppelman GH, Vonk JM, Bruinenberg M, Schouten JP, Postma DS. Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms. J Allergy Clin Immunol 2008; 121:1510-3.

Dijstelbloem HM, Bijl M, Fijnheer R et al. Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum 2000; 43:2793-800.

Dikopoulos N, Schmid RM, Bachem M et al. Bile synthesis in rat models of inflammatory bowel diseases. Eur J Clin Invest 2007; 37:222-30.

Dilger K, Cascorbi I, Grünhage F, Hohenester S, Sauerbruch T, Beuers U. Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. Liver Int 2006; 26:285-90.

Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics 1999; 9:551-9.

Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 2000; 67:512-20.

Dilger K, Meisel P, Hofmann U, Eichelbaum M. Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert’s syndrome. Ther Drug Monit 2000; 22:366-8.

Dilger K, Schwab M, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 2004; 10:578-83.

Dilmaghanian S, Gerber JG, Filler SG, Sánchez A, Gal J. Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. Chirality 2004; 16:79-85.

Dimaraki EV, Jaffe CA. Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab 2003; 88:3113-6.

DiMauro S, Gurgel-Giannetti J. The expanding phenotype of mitochondrial myopathy. Curr Opin Neurol 2005; 18:538-42.

Dimitroulakos J, Lorimer IA, Goss G. Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin Cancer Res 2006; 12:4426-31.

Din OS, Dodwell D, Winter MC, Mori S, Coleman RE. Current opinion of aromatase inhibitor-induced Arthralgia in breast cancer in the UK. Clin Oncol 2011. doi:10. 1016/j. clon. 2011. 06. 007.

Dinamarca MC, Cerpa W, Garrido J, Hancke JL, Inestrosa NC. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer’s amyloid-beta-deposits. Mol Psychiatry 2006; 11:1032-48.

Ding D, Xu L, Menon M, Reddy GP, Barrack ER. Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate 2005; 62:133-9.

Ding FX, Shen HC, Wilsie LC et al. Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A. Bioorg Med Chem Lett 2010; 20:3372-5.

Ding H, Cui G, Zhang L et al. Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population. Pharmacogenet Genomics 2010; 20:187-94.

Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:1069-75.

Ding PR, Tiwari AK, Ohnuma S et al. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One 2011. doi:10. 1371/journal. pone. 0019329.

Ding PY, Hu OY, Pool PE, Liao W. Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors? J Hum Hypertens 2000; 14:163-70.

Ding S, Yao D, Burchell B, Wolf CR, Friedberg T. High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by coexpressed human P450 reductase and hemin supplementation. Arch Biochem Biophys 1997; 348:403-10.

Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003; 43:149-73.

Ding X, Lichti K, Staudinger JL. The mycoestrogen zearalenone induces CYP3A through activation of the pregnane X receptor. Toxicol Sci 2006; 91:448-55.

Dingemanse J, Schaarschmidt D, van Giersbergen PL. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet 2003; 42:293-301.

Dingemanse J, van Giersbergen PL. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int J Clin Pharmacol Ther 2002; 40:310-6.

Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43:1089-115.

Diniz BS, Talib LL, Joaquim HP, de Paula VR, Gattaz WF, Forlenza OV. Platelet GSK3B activity in patients with late-life depression: Marker of depressive episode severity and cognitive impairment? World J Biol Psychiatry 2011; 12:216-22.

Dionne IJ, Garant MJ, Nolan AA et al. Association between obesity and a polymorphism in the beta(1)-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women. Int J Obes Relat Metab Disord 2002; 26:633-9.

Diotel N, do Rego JL, Anglade I et al. Activity and expression of steroidogenic enzymes in the brain of adult zebrafish. Eur J Neurosci 2011; 34:45-56.

Diotel N, Vaillant C, Gueguen MM et al. Cxcr4 and Cxcl12 expression in radial glial cells of the brain of adult zebrafish. J Comp Neurol 2010; 518:4855-76.

Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther 2004; 42:701-18.

Dishy V, Landau R, Sofowora GG et al. Beta-2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics 2004; 14:517-22.

Dishy V, Sofowora GG, Xie HG et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345:1030-5.

Dispenzieri A, Gertz MA, Lacy MQ et al. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 2006; 91:390-3.

Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985; 260:9057-67.

Dittrich C, Zandvliet AS, Gneist M, Huitema AD, King AA, Wanders J. A phase I and pharmacokinetic study of indisulam in combination with carboplatin. Br J Cancer 2007; 96:559-66.

DiTusa L, Luzier AB. Potential interaction between troglitazone and atorvastatin. J Clin Pharm Ther 2000; 25:279-82.

Dixit V, Hariparsad N, Desai P, Unadkat JD. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharm Drug Dispos 2007; 28:257-62.

Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007; 35:1853-9.

Dixon CM, Colthup PV, Serabjit-Singh CJ et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995; 23:1225-30.

Dixon DL, Williams VG. Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy 2009; 29:744-8.

Dixon MB, Lien YH. Tolvaptan and its potential in the treatment of hyponatremia. Ther Clin Risk Manag 2008; 4:1149-55.

Djaffar Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep 2011; 38:5449-52.

Djaffar-Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Pharmacogenetics of coumarin dosing: Prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population. Genet Test Mol Biomarkers 2011; 15:827-30.

Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E, Mougenot JF, Bach JF, Caillat-Zucman S. CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut 1998; 43:187-9.

Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. Eur J Clin Pharmacol 2010; 66:571-8.

Djousse L, Knowlton B, Hayden M et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet 2003; 119:279-82.

Djuv A, Nilsen OG. Aloe vera juice: IC(50) and dual mechanistic inhibition of CYP3A4 and CYP2D6. Phytother Res 2011. doi:10. 1002/ptr. 3564.

Dlugos AM, Hamidovic A, Hodgkinson C et al. OPRM1 gene variants modulate amphetamine-induced euphoria in humans. Genes Brain Behav 2011; 10:199-209.

Dlugos AM, Hamidovic A, Palmer AA, de Wit H. Further evidence of association between amphetamine response and SLC6A2 gene variants. Psychopharmacology 2009; 206:501-11.

Dluhy RG. Pheochromocytoma-death of an axiom. New Eng J Med 2002; 346:1486-8.

Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A et al. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 2008; 9:1595-603.

Do Carmo EC, Fernandes T, Koike D et al. Anabolic steroid associated to physical training induces deleterious cardiac effects. Med Sci Sports Exerc 2011; 43:1836-48.

Do Carmo S, Fournier D, Mounier C, Rassart E. Human apolipoprotein D overexpression in transgenic mice induces insulin resistance and alters lipid metabolism. Am J Physiol Endocrinol Metab 2009; 296:802-11.

Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy 2009; 29:1089-102.

Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011; 90:117-25.

Dobrzycka B, Terlikowski SJ, Kowalczuk O, Niklińska W, Chyczewski L, Kulikowski M. Mutations in the KRAS gene in ovarian tumors. Folia Histochem Cytobiol 2009; 47:221-4.

Dočolomanský P, Boháčová V, Barančík M, Breier A. Why the xanthine derivatives are used to study of P-glycoprotein-mediated multidrug resistance in L1210/VCR line cells. Gen Physiol Biophys 2010; 29:215-21.

Dodart JC, Marr RA, Koistinaho M et al. Gene delivery of human apolipoprotein E alters brain amyloid-beta burden in a mouse model of Alzheimer’s disease. Proc Nat Acad Sci USA 2005; 102:1211-6.

Dodd S, Boulton DW, Burrows GD, DeVane CL, Norman TR. In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Hum Psychopharmacol 2001; 16:541-4.

Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010; 30:842-54.

Dodhia VR, Fantuzzi A, Gilardi G. Engineering human cytochrome P450 enzymes into catalytically self-sufficient chimeras using molecular Lego. J Biol Inorg Chem 2006; 11:903-16.

Doehmer J. V79 Chinese hamster cells genetically engineered for cytochrome P450 and their use in mutagenicity and metabolism studies. Toxicology 1993; 82:105-18.

Doehmer J, Schmalix WA, Greim H. Genetically engineered in vitro systems for biotransformation studies. Methods Find Exp Clin Pharmacol 1994; 16:513-8.

Doehmer J, Tewes B, Klein KU, Gritzko K, Muschick H, Mengs U. Assessment of drug-drug interaction for silymarin. Toxicol In Vitro 2008; 22:610-7.

Doehmer J, Weiss G, McGregor GP, Appel K. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol In Vitro 2011; 25:21-7.

Doehring A, Antoniades C, Channon KM, Tegeder I, Lötsch J. Clinical genetics of functionally mild non-coding GTP cyclohydrolase 1 (GCH1) polymorphisms modulating pain and cardiovascular risk. Mutat Res 2008; 659:195-201.

Dogan I, Onen HI, Yurdakul AS et al. Polymorphisms in the vitamin D receptor gene and risk of lung cancer. Med Sci Monit 2009; 15:232-42.

Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97:1037-41.

Doggen CJ, Kunz G, Rosendaal FR et al. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost 1998; 80:743-8.

Doherty E, Pakarinen P, Tiitinen A et al. A Novel mutation in the FSH receptor inhibiting signal transduction and causing primary ovarian failure. J Clin Endocrinol Metab 2002; 87:1151-5.

Dohmen K, Baraona E, Ishibashi H et al. Ethnic differences in gastric sigma-alcohol dehydrogenase activity and ethanol first-pass metabolism. Alcohol Clin Exp Res 1996; 20:1569-76.

Dohse M, Scharenberg C, Shukla S et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010; 38:1371-80.

Doh-ura K, Tamura K, Karube Y, Naito M, Tsuruo T, Kataoka Y. Chelating compound, chrysoidine, is more effective in both antiprion activity and brain endothelial permeability than quinacrine. Cell Mol Neurobiol 2007; 27:303-16.

Doh-ura K, Tateishi J, Sasaki H, Kitamoto T, Sakaki Y. Pro-to-leu change at position 102 of prion protein is the most common but not the sole mutation related to Gerstmann-Straussler syndrome. Biochem Biophys Res Commun 1989; 163:974-9.

Doi AM, Patterson PE, Gallagher EP. Variability in aflatoxin B(1)-macromolecular binding and relationship to biotransformation enzyme expression in human prenatal and adult liver. Toxicol Appl Pharmacol 2002; 181:48-59.

Doi H, Horie T. Salicylic acid-induced hepatotoxicity triggered by oxidative stress. Chem Biol Interact 2010; 183:363-8.

Doiron J, Soultan AH, Richard R et al. Synthesis and structure-activity relationship of 1- and 2-substituted-1,2,3-triazole letrozole-based analogues as aromatase inhibitors. Eur J Med Chem 2011; 46:4010-24.

Doki K, Homma M, Kuga K et al. Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol 2006; 62:919-26.

Doki K, Homma M, Kuga K et al. Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol 2007; 63:951-7.

Doki K, Homma M, Kuga K, Aonuma K, Kohda Y. Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. Br J Clin Pharmacol 2009; 68:89-96.

Dolder C, Nelson M, Stump A. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. Drugs Aging 2010; 27:625-40.

Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother 2008; 42:1822-31.

Doligalska M, Jóźwicka K, Kiersnowska M, Mroczek A, Pączkowski C, Janiszowska W. Triterpenoid saponins affect the function of P-glycoprotein and reduce the survival of the free-living stages of Heligmosomoides bakeri. Vet Parasitol 2011; 179:144-51.

Dolphin CT, Beckett DJ, Janmohamed A et al. The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein. J Biol Chem 1998; 273:30599-607.

Dolphin CT, Janmohamed A, Smith RL, Shephard EA, Phillips IR. Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat Genet 1997; 17:491-4.

Dolzan V, Plesnicar BK, Serretti A et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet 2007; 144:809-15.

Dollery CT. Beyond genomics. Clin Pharmacol Ther 2007; 82:366-70.

Dolley G, Bertrais S, Frochot V et al. Promoter adiponectin polymorphisms and waist/hip ratio variation in a prospective French adults study. Int J Obes 2008; 32:669-75.

Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59:386-92.

Domanski TL, He YA, Khan KK, Roussel F, Wang Q, Halpert JR. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 2001; 40:10150-60.

Dombrovski AY, Mulsant BH, Ferrell RE et al. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol 2010; 25:37-45.

Domingo P, Muñiz-Diaz E, Baraldès MA et al. Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med 2002; 112:19-25.

Domingues-Montanari S, Hernandez-Guillamon M, Fernandez-Cadenas I et al. ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. Neurobiol Aging 2011; 32:551.

Do-Monte FH, Allensworth M, Carobrez AP. Impairment of contextual conditioned fear extinction after microinjection of alpha-1-adrenergic blocker prazosin into the medial prefrontal cortex. Behav Brain Res 2010; 211:89-95.

Domschke K, Dannlowski U, Hohoff C et al. Neuropeptide Y (NPY) gene: Impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol 2010; 20:301-9.

Domschke K, Dannlowski U, Ohrmann P et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 2008; 18:751-9.

Donahue TR, Hines OJ. CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. World J Surg 2009; 33:710-5.

Donato MT, Gómez-Lechón MJ, Jover R, Nakamura T, Castell JV. Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture. J Pharmacol Exp Ther 1998; 284:760-7.

Donato MT, Jiménez N, Serralta A, Mir J, Castell JV, Gómez-Lechón MJ. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol In Vitro 2007; 21:271-6.

Donato MT, Lahoz A, Jiménez N et al. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 2006; 34:1556-62.

Doney AS, Lee S, Leese GP, Morris AD, Palmer CN. Increased cardiovascular morbidity and mortality in type 2 diabetes is associated with the glutathione S transferase theta-null genotype: a Go-DARTS study. Circulation 2005; 111:2927-34.

Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009; 14:1105-18.

Dong H, Haining RL, Thummel KE, Rettie AE, Nelson SD. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos 2000; 28:1397-400.

Dong HJ, Miao KR, Qiao C et al. Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population. Leuk Lymphoma 2011; 52:1003-9.

Dong HY, Shao JW, Chen JF, Wang T, Lin FP, Guo YH. Transcriptional regulation of cytochrome P450 3A4 by four kinds of traditional Chinese medicines. Zhongguo Zhong Yao Za Zhi 2008; 33:1014-7, 1089.

Dong J, Dai J, Zhang M, Hu Z, Shen H. Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis. J Gastroenterol Hepatol 2010; 25:1042-50.

Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem 2006; 97:433-47.

Dong L, Luo R, Tong Y, Cai X, Mao M, Yu D. Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: an analysis in a western Chinese pediatric population. Brain Res 2011; 1391:114-24.

Dong PP, Fang ZZ, Zhang YY et al. Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib. Acta Pharmacol Sin 2011; 32:399-407.

Dong S, Guo AL, Chen ZH et al. RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J Hematol Oncol 2010; 3:10.

Dong S, Li C, Wu P, Tsien JZ, Hu Y. Environment enrichment rescues the neurodegenerative phenotypes in presenilins-deficient mice. Eur J Neurosci 2007; 26:101-12.

Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology 2010; 139:464-73.

Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine 2010; 5:597-615.

Dong X, Wu J, Liang P, Li J, Yuan L, Liu X. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer: a meta-analysis. Arch Med Res 2010; 41:125-33.

Dong X, Zhao H, Ma X, Wang S. Reduction in bile acid pool causes delayed liver regeneration accompanied by down-regulated expression of FXR and c-Jun mRNA in rats. J Huazhong Univ Sci Technolog Med Sci 2010; 30:55-60.

Dong Z, Guo W, Zhou R et al. Polymorphisms of the DNA repair gene XPA and XPC and its correlation with gastric cardiac adenocarcinoma in a high incidence population in North China. J Clin Gastroenterol 2008; 42:910-5.

Donkin JJ, Stukas S, Hirsch-Reinshagen V et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem 2010; 285:34144-54.

Donlon TA, Harris P, Neve RL. Localization of microtubule-associated protein tau (MTBT1) to chromosome 17q21. Cytogenet Cell Genet 1987; 46:607.

Dönmez Y, Gündüz U. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed Pharmacother 2011; 65:85-9.

Donnelly JG. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Ther Drug Monit 2004; 26:231-5.

Donnelly LA, Doney AS, Dannfald J et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics 2008; 18:1021-6.

Donnelly LA, Palmer CNA, Whitley AL et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenetics Genomics 2008; 18:279-87.

Donner H, Braun J, Seidl C et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto’s thyroiditis and Addison’s disease. J Clin Endocrinol Metab 1997; 82:4130-2.

Donner H, Rau H, Braun J, Herwig J, Usadel KH, Badenhoop K. Highly polymorphic promoter regions of HLA DQA1 and DQB1 genes do not help to further define disease susceptibility in insulin-dependent diabetes mellitus. Tissue Antigens 1997; 50:642-5.

Donovan JL, Chavin KD, Devane CL et al. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32:906-8.

Donovan JL, DeVane CL, Chavin KD et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32:1333-6.

Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS. Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos 2003; 31:519-22.

Donovan JL, DeVane CL, Lewis JG et al. Effects of St John’s wort (Hypericum perforatum L. ) extract on plasma androgen concentrations in healthy men and women: a pilot study. Phytother Res 2005; 19:901-6.

Dooley TP, Huang Z. Genomic organization and DNA sequences of two human phenol sulfotransferase genes (STP1 and STP2) on the short arm of chromosome 16. Biochem Biophys Res Commun 1996; 228:134-40.

Doolin MT, Barbaux S, McDonnell M, Hoess K, Whitehead AS, Mitchell LE. Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. Am J Hum Genet 2002; 71:1222-6.

Doostdar H, Burke MD, Mayer RT. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 2000; 144:31-8.

Dorababu M, Nishimura A, Prabha T et al. Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. Biomed Pharmacother 2009; 63:697-702.

Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, Llerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003; 59:221-5.

Dorado P, Cavaco I, Cáceres MC, Piedade R, Ribeiro V, Llerena A. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol 2008; 64:967-70.

Dorado P, Peñas-Lledó EM, de la Rubia A, Llerena A. Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. Pharmacogenomics 2009; 10:1083-9.

Dorado P, Sosa-Macias MG, Peñas-Lledó EM et al. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics J 2011; 11:108-12.

Dorajoo R, Pereira BP, Yu Z et al. Role of multi-drug resistance-associated protein-1 transporter in statin-induced myopathy. Life Sci 2008; 82:823-30.

Dorak MT, Burnett AK, Worwood M. Hemochromatosis gene in leukemia and lymphoma. Leuk Lymphoma 2002; 43:467-77.

Dorak MT, Burnett AK, Worwood M. HFE gene mutations in susceptibility to childhood leukemia: HuGE review. Genet Med 2005; 7:159-68.

Dorfman R, Sandford A, Taylor C et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest 2008; 118:1040-9.

Doria A, Warram JH, Krolewski AS. Genetic predisposition to diabetic nephropathy: evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 1994; 43:690-5.

Dorian P. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther 2010; 15(4 Suppl):15-8.

Döring F, Rimbach G, Lodge JK. In silico search for single nucleotide polymorphisms in genes important in vitamin E homeostasis. IUBMB Life 2004; 56:615-20.

Dorn C, Bataille F, Gaebele E, Heilmann J, Hellerbrand C. Xanthohumol feeding does not impair organ function and homoeostasis in mice. Food Chem Toxicol 2010; 48:1890-7.

Dorn GW 2nd, Liggett SB. Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure. Clin Transl Sci 2008; 1:255-62.

Dorn GW 2nd. GRK mythology: G-protein receptor kinases in cardiovascular disease. J Mol Med 2009; 87:455-63.

Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy 2005; 25:335-44.

Dornbrook-Lavender KA, Pieper JA. Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy. Cardiovasc Drugs Ther 2003; 17:75-82.

Dorne JL. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation. Fundam Clin Pharmacol 2004; 18:609-20.

Dorne JL, Walton K, Renwick AG. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem Toxicol 2003; 41:201-24.

Dorne JL, Walton K, Renwick AG. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem Toxicol 2005; 43:203-16.

Dorne JL, Walton K, Slob W, Renwick AG. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food Chem Toxicol 2002; 40:1633-56.

Dörner B, Kuntner C, Bankstahl JP et al. Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem 2009; 52:6073-82.

Dörner B, Kuntner C, Bankstahl JP et al. Radiosynthesis and in vivo evaluation of 1-[(18)F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorg Med Chem 2011; 19:2190-8.

Dornetshuber R, Heffeter P, Sulyok M et al. Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin. Mol Nutr Food Res 2009; 53:904-20.

Doroshyenko O, Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet 2009; 48:281-302.

Dorr RT, Alberts DS. Modulation of experimental doxorubicin skin toxicity by beta-adrenergic compounds. Cancer Res 1981; 41:2428-32.

Dos Santos C, Essioux L, Teinturier C et al. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 2004; 36:720-4.

Doshi U, Li AP. Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction. J Biomol Screen 2011; 16:903-9.

Dostalek M, Court MH, Hazarika S, Akhlaghi F. Diabetes mellitus reduces qctivity of human UDP-Glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos 2011; 39:448-55.

Dou J, Jiang C, Wang J et al. Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol Int 2011; 35:227-34.

Doupis J, Veves A. DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther 2008; 25:627-43.

Douvaras P, Antonatos DG, Kekou K et al. Association of VEGF gene polymorphisms with the development of heart failure in patients after myocardial infarction. Cardiology 2009; 114:11-8.

Dowless MS, Barbee JL, Borchert KM, Bocchinfuso WP, Houck KA. Cyclic AMP-independent activation of CYP3A4 gene expression by forskolin. Eur J Pharmacol 2005; 512:9-13.

Downs JR, Clearfield M, Tyroler HA et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87:1074-9.

Dracopoli NC, Fountain JW. CDKN2 mutations in melanoma. Cancer Surv 1996; 26:115-32.

Drăgan CA, Peters FT, Bour P et al. Convenient gram-scale metabolite synthesis by engineered fission yeast strains expressing functional human P450 systems. Appl Biochem Biotechnol 2011; 163:965-80.

Dragic T, Litwin V, Allaway GP et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-73.

Dragin N, Shi Z, Madan R et al. Phenotype of the Cyp1a1/1a2/1b1-/- triple-knockout mouse. Mol Pharmacol 2008; 73:1844-56.

Drago A, Alboni S, Nicoletta B, de Ronchi D, Serretti A. HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory. Eur J Clin Pharmacol 2010; 66:5-27.

Drago A, de Ronchi D, Serretti A. Pharmacogenetics of antidepressant response: an update. Hum Genomics 2009; 3:257-74.

Drago A, Ronchi DD, Serretti A. 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Int J Neuropsychopharmacol 2008; 11:701-21.

Drago A, Ronchi DD, Serretti A. Pharmacogenetics of antidepressant response: an update. Hum Genomics 2009; 3:257-74.

Drago A, Serretti A. Focus on HTR2C: A possible suggestion for genetic studies of complex disorders. Am J Med Genet B Neuropsychiatr Genet 2009; 150:601-37.

Dragoni S, Bellik L, Frosini M et al. l-Deprenyl metabolism by the cytochrome P450 system in monkey (Cercopithecus aethiops) liver microsomes. Xenobiotica 2003; 33:181-95.

Draheim V, Reichel A, Weitschies W, Moenning U. N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes. Eur J Pharm Sci 2010; 41:201-9.

Drahushuk AT, McGarrigle BP, Larsen KE, Stegeman JJ, Olson JR. Detection of CYP1A1 protein in human liver and induction by TCDD in precision-cut liver slices incubated in dynamic organ culture. Carcinogenesis 1998; 19:1361-8.

Drakenberg K, Nikoshkov A, Horváth MC et al. Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci USA 2006; 103:7883-8.

Draper DW, Madenspacher JH, Dixon D, King DH, Remaley AT, Fessler MB. ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung. Am J Respir Crit Care Med 2010; 182:404-12.

Drazen JM, Yandava CN, Dube L et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:168-70.

Dreiseitel A, Oosterhuis B, Vukman KV et al. Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br J Pharmacol 2009; 158:1942-50.

Dreiseitel A, Schreier P, Oehme A, Locher S, Hajak G, Sand PG. Anthocyanins and their metabolites are weak inhibitors of cytochrome P450 3A4. Mol Nutr Food Res 2008; 52:1428-33.

Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest 2007; 117:3603-9.

Dresser GK, Bailey DG. A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol 2002; 9:191-8.

Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003; 33 Suppl 2:10-6.

Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38:41-57.

Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 2002; 72:247-55.

Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology 2004; 43:1405-8.

Drigo I, Piscianz E, Valencic E et al. Selective resistance to different glucocorticoids in severe autoimmune disorders. Clin Immunol 2010; 134:313-9.

Dring MM, Goulding CA, Trimble VI et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 2006; 130:341-8.

Driver KE, Song H, Lesueur F et al. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis 2008; 29:333-41.

Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 2002; 277:25125-32.

Drocourt L, Pascussi JM, Assenat E, Fabre JM, Maurel P, Vilarem MJ. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab Dispos 2001; 29:1325-31.

Drögemöller BI, Wright GE, Niehaus DJ et al. Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 2010; 11:1095-103.

Drolet B, Rousseau G, Daleau P, Cardinal R, Simard C, Turgeon J. Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. J Cardiovasc Pharmacol Ther 2001; 6:255-60.

Drolet B, Yang T, Daleau P, Roden DM, Turgeon J. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol 2003; 41:934-7.

Drover VAB, Wong NCW, Agellon LB. A distinct thyroid hormone response element mediates repression of the human cholesterol 7-alpha-hydroxylase (CYP7A1) gene promoter. Mol Endocr 2002; 16:14-23.

Droździk M, Białecka M, Myśliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease. Pharmacogenetics 2003; 13:259-63.

Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J 2007; 7:404-7.

Drumm ML, Konstan MW, Schluchter MD et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005; 353:1443-53.

D’Souza DL, Dimmitt DC, Robbins DK, Nezamis J, Simms L, Koch KM. Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol 2001; 41:455-8.

D’Souza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM. Effect of alosetron on the pharmacokinetics of alprazolam. J Clin Pharmacol 2001; 41:452-4.

Du J, Xing Q, Xu L et al. Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 2006; 7:831-41.

Du J, Xu Y, Duan S et al. A case-control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1200-4.

Du J, Zhang A, Wang L et al. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol 2010; 24:1115-20.

Du L, Li M. Modeling the Interactions Between alpha(1)-Adrenergic Receptors and Their Antagonists. Curr Comput Aided Drug Des 2010; 6:165-78.

Du L, Neis MM, Ladd PA, Keeney DS. Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. J Pharmacol Exp Ther 2006; 319:1162-71.

du Plooy M, Viljoen M, Rheeders M. Evidence for time-dependent interactions between ritonavir and lopinavir/ritonavir plasma levels following P-glycoprotein inhibition in Sprague-Dawley rats. Biol Pharm Bull 2011; 34:66-70.

Du Preez J, Matolweni LO, Greenberg J, Mntla P, Adeyemo AA, Mayosi BM. The alpha 2C Del322-325 adrenergic receptor polymorphism is not associated with heart failure due to idiopathic dilated cardiomyopathy in black Africans. Cardiovasc J Afr 2008; 19:15-6.

DU SS, Yao KT. Expression of ATP-binding cassette transporter genes in nasopharyngeal carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28:449-52.

Du Z, Qin R, Wei C et al. Pancreatic cancer cells resistant to chemoradiotherapy rich in “stem-cell-like” tumor cells. Dig Dis Sci 2011; 56:741-50.

Duan J, Martinez M, Sanders AR et al. DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: ssociation evidence in the 3’ end of the gene. Hum Hered 2007; 64:97-106.

Duan W, Guo Z, Jiang H et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 2004; 55:590-4.

Duan W, Sun B, Li TW, Tan BJ, Lee MK, Teo TS. Cloning and characterization of AWP1, a novel protein that associates with serine/threonine kinase PRK1 in vivo. Gene 2000; 256:113-21.

Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, Hornicek FJ. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol 2009; 63:1121-9.

Duara R, Loewenstein DA, Greig MT et al. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am J Geriatr Psychiatry 2011; 19:951-60.

Duarte N, Ramalhete C, Varga A, Molnár J, Ferreira MJ. Multidrug resistance modulation and apoptosis induction of cancer cells by terpenic compounds isolated from Euphorbia species. Anticancer Res 2009; 29:4467-72.

Dubelaar EJ, Verwer RW, Hofman MA, van Heerikhuize JJ, Ravid R, Swaab DE. ApoE epsilon4 genotype is accompanied by lower metabolic activity in nucleous basalis of Meynert neurons in Alzheimer patients and controls as indicated by the size of the Golgi apparatus. J Neuropathol Exp Neurol 2004; 63:159-69.

Dubertret C, Hanoun N, Adès J, Hamon M, Gorwood P. Family-based association study of the serotonin-6 receptor gene (C267T polymorphism) in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 126:10-5.

Dubey RK, Gillespie DG, Zacharia LC, Barchiesi F, Imthurn B, Jackson EK. CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension 2003; 41:807-13.

Dubey S, Hutson P, Alberti D et al. Phase I study of docetaxel and topotecan in patients with advanced malignancies. J Oncol Pharm Pract 2005; 11:131-8.

Dubin RL, Hall CM, Pileri CL et al. Thermostable (SULT1A1) and thermolabile (SULT1A3) phenol sulfotransferases in human osteosarcoma and osteoblast cells. Bone 2001; 28:617-24.

Dubovsky SL, Warren C. Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin Investig Drugs 2009; 18:1533-40.

Duca RC, Mabondzo A, Bravin F, Delaforge M. In vivo effects of zearalenone on the expression of proteins involved in the detoxification of rat xenobiotics. Environ Toxicol 2010. doi:10. 1002/tox. 20617.

Ducharme MP, Bernstein ML, Granvil CP, Gehrcke B, Wainer IW. Phenytoin-induced alteration in the N-dechloroethylation of ifosfamide stereoisomers. Cancer Chemother Pharmacol 1997; 40:531-3.

Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993; 36:457-9.

Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996; 14:259-62.

Duester G, Hatfield GW, Buhler R, Hempel J, Jornvall H, Smith M. Molecular cloning and characterization of cDNA for the beta subunit of human alcohol dehydrogenase. Proc Nat Acad Sci USA 1984; 81:4055-9.

Duez H, van der Veen JN, Duhem C et al. Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. Gastroenterology 2008; 135:689-98.

Duff K, Eckman C, Zehr C et al. Increased amyloid-beta-42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383:710-3.

Dufficy L, Naumovski N, Ng X et al. G80A reduced folate carrier SNP influences the absorption and cellular translocation of dietary folate and its association with blood pressure in an elderly population. Life Sci 2006; 79:957-66.

Duffy TA, Picha ME, Won ET, Borski RJ, McElroy AE, Conover DO. Ontogenesis of gonadal aromatase gene expression in atlantic silverside (Menidia menidia) populations with genetic and temperature-dependent sex determination. J Exp Zool A Ecol Genet Physiol 2010; 313:421-31.

Dufort I, Labrie F, Luu-The V. Human types 1 and 3 3-alpha-hydroxysteroid dehydrogenases: differential lability and tissue distribution. J Clin Endocr Metab 2001; 86:841-6.

Dufour C, Capasso M, Svahn J et al. Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population. Br J Haematol 2004; 126:682-5.

Dufour C, Svahn J, Bacigalupo A et al. Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients. Haematologica 2005; 90:1027-31.

Duguay Y, Báár C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004; 75:223-33.

Duisken M, Sandner F, Blömeke B, Hollender J. Metabolism of 1,8-cineole by human cytochrome P450 enzymes: identification of a new hydroxylated metabolite. Biochim Biophys Acta 2005; 1722:304-11.

Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol 2004; 93:3-6.

Dulos J, Boots AH. DHEA metabolism in arthritis: a role for the p450 enzyme Cyp7b at the immune-endocrine crossroad. Ann N Y Acad Sci 2006; 1069:401-13.

Dumanis SB, Cha HJ, Song JM et al. ApoE receptor 2 regulates synapse and dendritic spine formation. PLoS One 2011. doi:10. 1371/journal. pone. 0017203.

Dumas I, Diorio C. Polymorphisms in genes involved in the estrogen pathway and mammographic density. BMC Cancer 2010; 10:636.

Dumond JB, Vourvahis M, Rezk NL et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 2010; 87:735-42.

Dumont J, Jossé R, Lambert C et al. Preferential induction of the AhR gene battery in HepaRG cells after a single or repeated exposure to heterocyclic aromatic amines. Toxicol Appl Pharmacol 2010; 249:91-100.

Dumontet C, Landi S, Reiman T et al. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplant 2010; 45:1316-24.

Dunajska K, Lwow F, Milewicz A et al. beta(3)-adrenergic receptor polymorphism and metabolic syndrome in postmenopausal women. Gynecol Endocrinol 2008; 24:133-8.

Dunbar L, Miles W, Wheeler A, Sheridan J, Pulford J, Butler R. The CYP2D6 metaboliser status of patients prescribed risperidone for the treatment of psychosis. N Z Med J 2009; 122:29-34.

Dunbier AK, Anderson H, Ghazoui Z et al. ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25. 1. PLoS Genet 2011. doi:10. 1371/journal. pgen. 1001382.

Duncan AMV, Anderson LL, Funk CD, Abramovitz M, Adam M. Chromosomal localization of the human prostanoid receptor gene family. Genomics 1995; 25:740-2.

Duncan JA, Scholey JW, Miller JA. Angiotensin II type 1 receptor gene polymorphisms in humans: physiology and pathophysiology of the genotypes. Curr Opin Nephrol Hypertens 2001; 10:111-6.

Duncan KA, Saldanha CJ. Neuroinflammation induces glial aromatase expression in the uninjured songbird brain. J Neuroinflammation 2011; 8:81.

Dunér P, To F, Beckmann K et al. Immunization of apoE-/- mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis. Cardiovasc Res 2011; 91:528-36.

Duniec-Dmuchowski Z, Ellis E, Strom SC, Kocarek TA. Regulation of CYP3A4 and CYP2B6 expression by liver X receptor agonists. Biochem Pharmacol 2007; 74:1535-40.

Duniec-Dmuchowski Z, Fang HL, Strom SC, Ellis E, Runge-Morris M, Kocarek TA. Human pregnane X receptor activation and CYP3A4/CYP2B6 induction by 2,3-oxidosqualene:lanosterol cyclase inhibition. Drug Metab Dispos 2009; 37:900-8.

Dunn BK, Greene MH, Kelley JM et al. Novel pathway analysis of genomic polymorphism-cancer risk interaction in the breast cancer prevention trial. Int J Mol Epidemiol Genet 2010; 1:332-49.

Dunn S, Hedges L, Sampson K et al. Pharmacokinetic interaction of the antiparasitic agents ivermectin and spinosad in dogs. Drug Metab Dispos 2011; 39:789-95.

Dunne G, Breen L, Collins DM, Roche S, Clynes M, O’Connor R. Modulation of P-gp expression by lapatinib. Invest New Drugs 2011; 29:1284-93.

Dupuis J, Langenberg C, Prokopenko I et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42:105-16.

Dupuy AM, Mas E, Ritchie K et al. The relationship between apolipoprotein E4 and lipid metabolism is impaired in Alzheimer’s disease. Gerontology 2001; 47:213-8.

Dupuy J, Alvinerie M, Ménez C, Lespine A. Interaction of anthelmintic drugs with P-glycoprotein in recombinant LLC-PK1-mdr1a cells. Chem Biol Interact 2010; 186:280-6.

Durand JP, Gourmel B, Mir O, Goldwasser F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 2007; 18:808-9.

Durany N, Riederer P, Cruz-Sanchez FF. Apoliprotein E genotype in Spanish schizophrenic patients. Psychiatr Genet 2000; 10:73-7.

Dure L, Landwehrmeyer G, Golden J et al. IT15 gene expression in fetal human brain. Brain Res 1994; 659:33-41.

Duret C, Daujat-Chavanieu M, Pascussi JM et al. Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol 2006; 70:329-39.

Durgan DJ, Smith JK, Hotze MA et al. Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin. Am J Physiol Heart Circ Physiol 2006; 290:2480-97.

Durić G, Svetel M, Nikolaevic SI, Dragadević N, Gavrilović J, Kostić VS. Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson’s disease. Vojnosanit Pregl 2007; 64:25-30.

Duroudier NP, Tulah AS, Sayers I. Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy 2009; 64:823-39.

Dürr D, Stieger B, Kullak-Ublick GA et al. St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68:598-604.

Durrmeyer X, Hovhannisyan S, Médard Y et al. Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants? PLoS One 2010. doi:10. 1371/journal. pone. 0012329.

Dusseaux M, Martin E, Serriari N et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 2011; 117:1250-9.

Dutheil F, Beaune P, Tzourio C, Loriot MA, Elbaz A. Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. Arch Neurol 2010; 67:739-45.

Dutheil F, Dauchy S, Diry M et al. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 2009; 37:1528-38.

Dutta S, Das S, Guhathakurta S et al. Glutamate receptor 6 gene (GluR6 or GRIK2) polymorphisms in the Indian population: a genetic association study on autism spectrum disorder. Cell Mol Neurobiol 2007; 27:1035-47.

Duyao M, Ambrose C, Myers R et al. Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat Genet 1993; 4:387-92.

Duyao M, Auerbach A, Ryan A et al. Inactivation of the mouse Hungtington’s disease gene homolog Hdh. Sciece 1995; 269:407-10.

Duysen EG, Li B, Lockridge O. The butyrylcholinesterase knockout mouse a research tool in the study of drug sensitivity, bio-distribution, obesity and Alzheimer’s disease. Expert Opin Drug Metab Toxicol 2009; 5:523-8.

Dvir E, Friedman JE, Lee JY et al. A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer’s disease model. J Pharmacol Exp Ther 2006; 318:1248-56.

Dvorák Z, Modriansky M, Pichard-Garcia L et al. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol 2003; 64:160-9.

Dvorák Z, Ulrichová J, Modrianský M, Maurel P. Effect of colchicine and its derivatives on the expression of selected isoforms of cytochrome P450 in primary cultures of human hepatocytes. Acta Univ Palacki Olomuc Fac Med 2000; 143:47-50.

Dvorak Z, Ulrichova J, Pichard-Garcia L, Modriansky M, Maurel P. Comparative effect of colchicine and colchiceine on cytotoxicity and CYP gene expression in primary human hepatocytes. Toxicol In Vitro 2002; 16:219-27.

Dvořák Z, Vrzal R, Starha P, Klanicová A, Trávníček Z. Effects of dinuclear copper(II) complexes with 6-(benzylamino)purine derivatives on AhR and PXR dependent expression of cytochromes P450 CYP1A2 and CYP3A4 genes in primary cultures of human hepatocytes. Toxicol In Vitro 2010; 24:425-9.

Dwyer JH, Allayee H, Dwyer KM et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. New Eng J Med 2004; 350:29-37.

Dyer R, McMurray C. Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Nat Genet 2001; 29:270-8.

Dziedziejko V, Kurzawski M, Safranow K, Chlubek D, Pawlik A. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 2010; 12:41-7.